Design characteristics of Sequential Multiple Assignment Randomized Trials (SMARTs) for human health: a scoping review of studies between 2009-2024

Nikki L. B. Freeman,[1,2**] Sydney E. Browder,[3**] Bryce T. Rowland,[4,5] Emily P. Jones,[6] Margaret Hoch,[4] Alice H. Kim,[7] Christina W. Zhou,[4] Anna R. Kahkoska,[8,9,10] Katharine L. McGinigle,[11] Anastasia Ivanova,[4] Michael R. Kosorok,[4,12] and Kevin J. Anstrom[4,5]

[1]Department of Biostatistics and Bioinformatics, Duke University, Durham, NC
[2]Duke Clinical Research Institute, Duke University, Durham, NC
[3]Department of Epidemiology, University of North Carolina, Chapel Hill, NC
[4]Department of Biostatistics, University of North Carolina, Chapel Hill, NC
[5]Collaborative Studies Coordinating Center, University of North Carolina, Chapel Hill, NC
[7]School of Data Science and Society, University of North Carolina, Chapel Hill, NC
[6]Health Sciences Library, University of North Carolina, Chapel Hill, NC
[8]Department of Nutrition, University of North Carolina, Chapel Hill, NC
[9]Division of Endocrinology and Metabolism, University of North Carolina, Chapel Hill, NC
[10]Center for Aging and Health, University of North Carolina, Chapel Hill, NC
[11]Division of Vascular Surgery, University of North Carolina, Chapel Hill, NC
[12]Department of Statistics and Operations Research, University of North Carolina, Chapel Hill, NC

**Denotes co-first authorship

Corresponding author:
Nikki L. B. Freeman
300 W. Morgan St.
Durham, NC 27701, USA
Nikki.freeman@duke.edu

Word count: 3081/3500
References: 101
Tables: 4
Figures: 2
Supporting material: 7 items (4 documents, 3 tables)

STRUCTURED ABSTRACT
Objective: To characterize the reporting practices of sequential multiple assignment randomized trials (SMARTs) in human health research.

Design: Scoping review of protocol and primary analysis papers describing SMARTs published between January 2009 and January 2024.

Background: SMARTs are innovative trial designs that allow for multiple stages of randomization to treatment based on a patient's responses to previous treatments. They are uniquely designed to develop sequential adaptive interventions (dynamic treatment regimes) to support clinical decision-making over time. Previous reviews have identified inconsistencies in how the design, implementation, and results have been reported in published studies. A comprehensive assessment of SMART reporting practices is lacking, and necessary for developing standardized SMART-specific reporting guidelines.

Methods: We systematically searched multiple databases for SMART-related protocol and primary analysis papers published between January 2009 and January 2024. Title, abstract, and full-text screenings were performed by pairs of reviewers, with disagreements resolved by consensus. Data extraction included study characteristics, design elements, and analytic approaches for embedded or tailored dynamic treatment regimes (DTRs). Results were synthesized qualitatively and presented descriptively.

Results: From 5486 screened studies, 88 (59 protocols, 29 primary analyses) met inclusion criteria. Most studies targeted adults (62.7% protocols, 58.6% primary analyses) and were primarily conducted in the United States. Behavioral and mental health constituted the most frequent therapeutic domain. While intervention descriptions and re-randomization criteria were consistently reported, operational characteristics such as blinding (protocols: 64.4%, primary analyses: 69.0%) and randomization details (protocols: 88.1%, primary analyses: 75.9%) were inconsistently documented. Only 48.3% of primary analyses evaluated embedded DTRs, and none explored tailored DTRs.

Conclusions: Despite the increased adoption of SMART designs, substantial reporting variability persists. Most primary analyses underutilize the capability of SMARTs to generate data for developing dynamic treatment regimes. SMART-specific standardized reporting guidelines can help accelerate the scientific and clinical impact of SMARTs.

Strengths and limitations of this study

Strengths

- This is the most comprehensive review of SMARTs in human health to date, spanning studies published since SMARTS were introduced, and over a 15-year period (2009-2024).
- Rigorous methodology, including dual independent screening and extraction, enhances the reliability of the findings.

- The granularity of our assessment of design elements provides specific targets for developing SMART reporting guidelines.

Limitations

- This study only included protocol and primary analysis papers, missing SMARTs described in trial registries alone as well as analyses of SMARTs in secondary analysis papers.
- This review included only English-language publications, potentially missing relevant studies published in other languages
- This review did not assess the quality of the included SMARTs themselves, focusing instead on reporting practices.

INTRODUCTION

Sequential multiple assignment randomized trials (SMARTs), designed to mirror the dynamic of real-world clinical decision-making where medical providers and their patients often make decisions over time and in response to evolving health status and the effects of prior treatments, are a significant advancement in clinical research(1). Formalized by Murphy and Bingham(2), "a SMART is a type of multistage, factorial randomized trial, in which some or all participants are randomized at 2 or more decision points. Whether a patient is randomized at the second or a later decision point, and the available treatment options, may depend on the patient's response to prior treatment"(3). **Figure 1** illustrates an example of how a SMART may be designed.

SMARTs can be used to answer questions regarding main effects of first-line treatments as well as the effects of second-line treatments(1). By formalizing the treatment decision process via multiple randomizations, SMARTs can also generate evidence for treatment strategies that can adapt to individuals' unique, possibly evolving characteristics over the course of multiple treatment decisions. These treatment strategies are often evaluated in the analysis of a SMART by studying dynamic treatment regimes (DTRs), defined as a sequence of decision rules that map patient characteristics to a recommended treatment decision(4,5). Embedded DTRs are treatment sequences predefined within a SMART by the study design. In contrast, optimal tailored dynamic treatment regimes are DTRs that can be learned from SMART data using techniques from machine learning and reinforcement learning, but are generally not embedded in the trial itself(1). They are optimal in the sense that they attempt to generate rules that, if followed, would optimize outcomes on average in the population.

Given the flexibility of SMARTs to address multiple, often interrelated clinical questions, they can complicate the traditional hierarchy of primary, secondary, and exploratory analyses. In standard randomized controlled trials (RCTs), study objectives align with a primary hypothesis, guiding the selection of outcomes, sample size considerations, and how trial results are presented and reported. In contrast, the multipurpose nature of SMARTs makes it difficult to specify a single primary analysis, as the trial is not limited to answering one core question but rather is designed to inform a broader decision-making framework. Consequently, different researchers and trialists conducting may prioritize different aspects of the SMART design or which analyses are emphasized in published reports.

This analytic flexibility, while yielding methodological value and design efficiencies, may create substantial challenges for transparent and consistent reporting. SMARTs have been successfully conducted in multiple clinical domains, yet there is little consistency in how they are described in clinical literature. Lorenzoni et al.(6) conducted a systematic review examining SMART designs in oncology. They identified 33 records, including 15 trial reports, 4 protocols, and 14 trial registrations. They found that most studies analyzed each treatment stage separately rather than considering embedded treatment regimes. Moreover, they found that power calculations and study analyses primarily relied on statistical approaches traditionally used in single-stage parallel

designs. The authors concluded that formal reporting guidelines for SMART designs are needed.

Bigirumurame, Uwimpuhwe, and Wason(7) conducted a broader systematic review examining the reporting quality of SMART studies across various fields. They reviewed 157 records, including 12 trial reports, 24 protocols, 91 methodological papers, and 30 review papers. Their review highlighted that key components of SMART designs were inconsistently reported, with deficiencies in reporting parameters required for sample size calculations. They also found that most trials were powered using stage-specific aims rather than leveraging the full potential of SMART designs to evaluate embedded adaptive interventions. Additionally, they noted that few studies (16.67%) were interested in determining the best embedded adaptive interventions, and most trials did not report information about multiple testing adjustment.

These findings underscore a persistent gap in the report of the design, implementation, and results of SMARTs, hindering the interpretation, replication, and synthesis of evidence from SMARTs and limiting their scientific and clinical impact. The objective of this review was to systematically characterize the reporting practices of SMARTs in human health research, with a focus on design features and methodological transparency. We examined only protocol and primary analysis papers to provide a focused assessment of how SMARTs are initially designed and subsequently reported. We have also conducted a more granular analysis of how embedded regimes and deeply tailored regimes are reported and analyzed, an aspect only briefly touched upon in previous reviews. Finally, our review specifically aims to inform the development of reporting guidelines for SMARTs, addressing the gap identified by both previous reviews. This review's findings can directly inform the development of SMART-specific reporting guidelines, similar to CONSORT for traditional RCTs, and enhance methodological transparency and rigor.

METHODS

We used the PRISMA extension for scoping reviews (PRSIMA-ScR)(8) to guide our process and the full checklist is included (**Supplementary document 4**). A detailed protocol, including methods and objectives, was prospectively developed and made publicly available through the Open Science Framework(9). Our inclusion and exclusion criteria were developed to ensure a comprehensive and coherent examination of SMARTs in human health contexts. We limited inclusion to studies published from January 2009 through February 9, 2024, since the terminology for SMARTs was introduced in 2009. Protocol, design, primary analysis, and secondary analysis papers, as well as registered trials that the authors identified as SMARTs conducted in a human health care setting, were included in the search. Articles not in English, reviews, commentaries, letters, editorials, theses, and methodological papers were excluded. A detailed description of the full inclusion and exclusion criteria is provided in the protocol **(Supplementary document 1).**

A medical librarian (EJ) developed a comprehensive search strategy to identify potentially relevant publications in PubMed (U.S. National Library of Medicine, National Institutes of Health), Scopus (Elsevier), Embase (Elsevier), and Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library). The search strategy used a combination of controlled vocabulary, when applicable, and various keywords for

SMART (**Supplementary document 2**). Databases were searched on February 9, 2024. Search strategies for all databases are available in the supplemental appendix. Results were imported into Endnote and deduplicated; all unique citations were then imported into Covidence for screening.

Before commencing with the title and abstract screening, benchmark screenings were conducted, each on 100 titles and abstracts, until inter-rater reliability measured by Cohen's kappa was >70% between screeners. Each title and abstract were screened independently by two reviewers (SB, MH, TF, CZ) and conflicts were adjudicated by a third author (NF or BR). Studies that clearly did not meet the eligibility criteria were excluded. Full-text screening for each paper was independently performed by two reviewers (MH, TF, CZ), and reasons for articles to be excluded at this stage were noted. Conflicts were adjudicated by a third author (NF).

A standardized data extraction form developed in Microsoft Excel was piloted by the review team. Data items extracted included study characteristics (e.g., authors, publication year, country), design characteristics of the SMART designs (e.g., number of randomizations, treatment options), and operational characteristics (e.g., blinding, randomization strategies). A comprehensive list of the data items extracted are provided in **Supplementary document 3**. Extraction of the data items from full texts into the extraction form was conducted by two independent extractors (SB, MH, AK, CZ, NF, AD). Since our goal was to examine how SMARTs are reported, no additional data were sought from investigators. Two authors (NF, SB) synthesized the results from the duplicate data extraction. Patterns across the protocol and primary analysis papers were identified and described. Patients and members of the public were not involved in the design, conduct, reporting, or dissemination plans of this scoping review.

RESULTS

We identified 10,066 citations through database searches and 4,580 were duplicates. The remaining 5,486 citations were imported into Covidence for title/abstract screening and 4,657 were deemed irrelevant. Full-text publications were retrieved for all remaining records (n = 829) and screened for inclusion. Of these, 532 reports were excluded, primarily for not being a SMART. The remaining 297 articles were assessed for inclusion in the data extraction stage, with 209 excluded mostly due to being registry entries, secondary analyses, or non-original research. In total, 88 studies were included in our analysis, including 59 protocol and 29 primary analysis papers. The PRISMA Flow Diagram depicting the full study selection process can be found in **Figure 2.**

Characteristics of the included studies are summarized in **Table 1**. Seven (11.9%) protocol papers and 10 (34.5%) primary analysis papers were about pilot interventions. Most protocol and primary analysis papers evaluated the efficacy and/or effectiveness of the proposed interventions [n=52 (88.1%) and n=21 (72.4%), respectively], while 25 (42.4%) protocol papers and 10 (32.5%) primary analysis papers assessed implementation, feasibility, and/or acceptability. Eighteen papers (17 protocol and 1 primary) evaluated the cost-effectiveness of interventions. Most protocol and primary analysis papers about SMARTs were published in 2019 or later [n=49 (83.1%) protocol papers; n = 24 (82.8%) primary analysis papers] and most focused on adult populations [n=37 (62.7%) protocol papers; n=17 (58.6%) primary analysis papers]. Additionally, some studies targeted special populations such as Black adolescents, veterans, and

females (see **Table S1**). Studies were predominantly conducted in the United States [n=44 (74.6%) protocol papers; n=24 (82.8%) primary analysis papers]. Other countries represented included Brazil, China, Kenya, and South Africa. Two studies were conducted in multiple countries. Among protocol papers, most targeted a SMART with 500 or less participants (n= 40, 67.8%), and most primary analysis papers reported trials with 200 or less participants (n=19, 65.5%).

Behavioral and mental health, including substance use, was the most frequently studied therapeutic area (n=23 protocol papers; n=19 primary analysis papers), followed by infectious disease (n=8 protocol papers; n=1 primary analysis paper), overweight and obesity (n=4 protocol papers; n=3 primary analysis papers), and pain (n=4 protocol papers; n=1 primary analysis paper). Other disease areas included cancer, cardiometabolic disease including diabetes and cardiovascular disease, inflammatory disorders, and neurological disease or injury. Most SMARTs had 2 potential randomizations (n=55 protocol papers; n=28 primary analysis papers), although a few had up to 3 randomizations (n=3 protocol papers; n=1 primary analysis paper) and one had 6 randomizations (n=1 protocol paper).

Table 2 provides a full listing of the studies included in our review, in addition to each study's interventions, re-randomization criteria, and outcomes. Interventions were most commonly behavioral, pharmacological, or digital health based. Common criteria for progressing to second-stage interventions included predefined thresholds for clinical or behavioral non-response, such as insufficient symptom improvement, low engagement, or unmet adherence targets. Second-stage interventions typically involved either augmentation of the first-stage intervention with additional components or switching to alternative interventions.

Primary efficacy outcomes varied widely, reflecting the diverse clinical areas studied. Examples include depression severity (measured by PHQ-9), glycemic control, pain impact scores, viral suppression in HIV studies, adherence rates, and behavioral outcomes such as smoking abstinence or reduction in substance use. Secondary outcomes often addressed complementary clinical measures, patient-reported outcomes, or psychosocial variables, such as anxiety, quality of life, sleep quality, physical activity levels, and patient satisfaction. Several studies reported additional outcomes related to feasibility, acceptability, cost-effectiveness, and implementation metrics.

Table 3 describes reporting on sample size, blinding, and randomization procedures. Most protocol papers (n=55, 93.2%) reported sample size calculations, with 74.6% (n=44) of those accounting for multiple randomizations. Whether or not blinding was discussed, even if to state that blinding was not possible or not undertaken, was described in approximately two-thirds of both protocol (n=38, 64.4%) and primary analysis (n=20, 69.0%) papers. Randomization details varied; about half reported first-stage allocation ratios [n=33 (55.9%) protocol papers; n=15 (51.7%) primary analysis papers], fewer reported later-stage allocations [n=31 (52.5%) protocol papers; n=11 (37.9%) primary analysis papers]. Stratification (protocol papers: 45.8%; primary

analysis: 31.0%) and blocking (protocol: 55.9%, primary analysis: 20.7%) were moderately common, whereas minimization was infrequent (protocol: 3.4%, primary analysis: 10.3%). Some papers (protocol: 11.9%, primary analysis: 24.1%) provided no randomization details. Full details are included in **Table S2**.

Table 4 describes the analysis of embedded DTRs and optimal DTRs. Of the 29 primary analysis papers reviewed, 14 (48.3%) analyzed embedded regimes, while none (0%) analyzed tailored regimes. Among the papers that analyzed embedded regimes, the most common statistical method was weighting and replication, used in 9 papers (31.0%). Other less frequently used analytical approaches included G-computation, marginal weighted least squares, longitudinal targeted maximum likelihood estimation (TMLE), GEE-based methods, and cubic polynomial modeling, each employed in only one (3.4%) paper. See **Table S3** for study-level characterization of DTR analysis approaches.

DISCUSSION

This comprehensive scoping review of eighty-eight studies, either planned, in process, or completed, reveals both the remarkable versatility of SMARTs across therapeutic domains and significant variability in reporting practices that may limit their full scientific impact.

Our work builds upon and extends previous efforts to characterize SMART reporting. As of April 2025, two reviews of SMARTs have been published, and two additional review protocols have been registered on PROSPERO. The two protocols describe studies that address highly specific questions, such as the methods used to assess SMART designs for psychosocial interventions targeting mental health disorders(10) and the effect of SMART designs among individuals with chronic disease(11). Similarly, the published review by Lorenzoni et al.[8] focused on SMART designs in oncology. The review published Bigirumurame et al.(7) primarily discussed deficient reporting of sample size calculation parameters and methods. Our review provides a timely, comprehensive examination of SMARTs across all health domains with a specific focus on an expanded set of design features. For example, while most papers described some aspect about blinding and randomization procedures, critical information like the first-stage allocation ratios were only reported about half of the time and even less frequently for later stage allocation ratios.

Similar to previous finding of insufficient sample size reporting(7), our review confirms and broadens this observation to additional key trial operational characteristics. In the papers we reviewed, intervention descriptions and re-randomization criteria were consistently well-documented, yet critical design elements—including blinding procedures, randomization allocation ratios, and randomization methods—were often inadequately reported or not reported at all. The inconsistent reporting of crucial SMART elements has significant implications. When essential trial design elements are inadequately described, it becomes difficult for readers and reviewers to assess the internal validity and methodological rigor of the trial. It may also lead to misinterpretation or misapplication of results in the future. Furthermore, funding agencies, institutional

review boards, and regulatory bodies may struggle to assess the feasibility or risk of SMARTs without a clear reporting framework. Thus, the threat of inconsistent reporting not only weakens scientific communication but also threatens the broader adoption and credibility of this otherwise promising trial design.

One reason why reporting for SMARTs is particularly challenging relates to a notable obstacle we encountered during this review. In our predefined extraction forms, we included fields specifically for primary, secondary, and tertiary or exploratory outcomes. However, several papers described primary and secondary aims rather than explicitly stating primary and secondary outcomes. This inconsistency highlights a fundamental complexity in SMART designs, as their unique structure allows multiple research questions to be addressed within a single trial. This contrasts with traditional RCTs, which typically have a narrower scope with fewer primary hypotheses. Consequently, an outcome considered primary for one research question within a SMART may differ when addressing another question within the same study. Moreover, there may be multiple, different aims targeting fundamentally different questions, obscuring traditional notions of primary, secondary, and tertiary analyses. This complexity has important implications beyond just outcome reporting; it also raises critical considerations regarding how SMARTs are planned and powered. For example, in an RCT, the sample size is typically calculated to detect a prespecified effect size for a clearly defined primary outcome. In contrast, when SMARTs lack a clear alignment between their multiple aims, hypotheses, and outcomes, it becomes unclear which comparisons the sample size calculation is intended to support and whether one well-powered aim necessarily implies that other aims are also well-powered.

Although the SMART framework inherently facilitates the evaluation of embedded and tailored dynamic treatment regimes (DTRs), our findings suggest underutilization of this capability in primary analyses. While we did not include secondary analysis papers in our review, the limited exploration of deeply tailored regimes within primary reports points to an opportunity for greater capitalization on the full analytical potential of data from SMARTs. Possible reasons for this underuse include risk aversion, limited familiarity with advanced analytical methods, and a lack of explicit methodological guidance. The limited analysis of embedded regimes and lack of analysis of tailored regimes in primary manuscripts represent a missed opportunity to fully leverage SMART data for precision medicine applications, potentially delaying the development of optimized adaptive and personalize interventions for clinical practice.

Unlike traditional randomized controlled trials (CONSORT)(12), systematic reviews (PRISMA)(13), and observational studies (STROBE)(14), which benefit from established reporting guidelines, SMARTs currently lack analogous standards. This absence threatens not only clear communication of study aims, methods, and findings but also limits the ability to properly evaluate the methodological rigor and quality of evidence generated from SMARTs. As our review demonstrates, critical elements such as sample size justification, randomization procedures, and outcome specification are often inconsistently reported, despite being essential for evaluating the validity and generalizability of trial findings. There is a clear need for the development of

standardized reporting guidelines specific to SMARTs, e.g., a CONSORT for SMARTs. Such guidelines would improve the clarity and completeness of reporting, support rigorous study design, and enhance the credibility and reproducibility of this promising trial framework, ultimately accelerating the translation of adaptive interventions into evidence-based clinical practice.

This scoping review has several limitations. Our inclusion criteria were limited to protocol and primary analysis papers published up to January 2024, excluding secondary analyses and registry entries. Additionally, identifying SMART designs through database searches can be challenging due to variability in terminology and inconsistent reporting practices. Thus, some relevant studies might have been inadvertently excluded. Despite these limitations, our findings provide valuable insights into current practices and gaps in SMART reporting and provide the most extensive scoping review of SMARTs to date.

This scoping review provides the most comprehensive examination of SMART reporting practices in human health research to date. Our findings reinforce the need for the clear alignment between study aims, outcomes, and analytic strategies; highlight the gaps in how fundamental design elements are documented; and show opportunities to better leverage SMARTs to generate adaptive treatment strategies. To fully realize the promise of SMARTs and the evidence they have the potential to generate, reporting guidelines tailored to the unique and innovative design of SMARTs is needed. Establishing such standards would strengthen the reproducibility and interpretability of SMARTs and accelerate the adoption of SMART-based evidence in clinical settings.

FUNDING
KJA, MK, and BR were supported by the National Institutes of Health through the NIH HEAL Initiative under award number 1U24AR076730. MK is additionally supported by the National Institutes of Health under award number UM1TR004406. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

AK is supported by the National Institutes on Aging, National Institutes of Health, through Grant K01-AG084971-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

SB is supported by the National Institute of Health through the UNC-Chapel Hill pre-doctoral Cardiovascular (CVD) Epidemiology Training Grant (NRSA: T32-HL007055-48). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

CONFLICT OF INTEREST

AUTHOR CONTRIBUTIONS
NF and BR conceived this review. The protocol was developed by NF, BR, EJ, AK, KM, MK, AI, and KA. EJ designed the search strategy. NF and BR managed title and

abstract screening. NF, SB, CZ, and MH conducted the full-text screening; NF, SB, CZ, MH, and AK extracted the articles. NF and SB synthesized the extraction results and wrote the first draft of the manuscript with KA. All authors provided feedback and approved the final manuscript. NF is the guarantor of this work, and as such, has full access to all the data and takes responsibility for the integrity of the data and the accuracy of the data analysis.

ACKNOWLEDGEMENTS
The authors would like to thank Timothy Feeney, Anthony Dickinson, Alexis Bryant, Abbey Foes, and Annika Cleven for courageously assisting in the development of the screening and extraction process.

Table 1. Study characteristics

Characteristics		
	Protocol papers (n=59) N (%)	**Primary analysis papers** (n=29) N (%)
Pilot study	7 (11.9%)	10 (34.5%)
Objective		
Efficacy and/or effectiveness	52 (88.1%)	21 (72.4%)
Implementation, feasibility, and/or acceptability	25 (42.4%)	10 (32.5%)
Cost-effectiveness	17 (28.8%)	1 (3.4%)
Publication year		
2009	1 (1.7%)	0 (0.0%)
2014	1 (1.7%)	0 (0.0%)
2015	0 (0.0%)	1 (3.4%)
2016	1 (1.7%)	2 (6.9%)
2017	2 (3.4%)	1 (3.4%)
2018	5 (17.2%)	1 (3.4%)
2019	6 (10.2%)	3 (10.3%)
2020	9 (15.3%)	4 (13.8%)
2021	8 (13.6%)	5 (17.2%)
2022	6 (10.2%)	4 (13.8%)
2023	18 (30.5%)	6 (20.7%)
2024	2 (3.4%)	2 (6.9%)
Country		
Australia	1 (1.7%)	0 (0.0%)
Brazil	0 (0.0%)	2 (6.9%)
Canada	0 (0.0%)	1 (3.4%)
China	3 (5.1%)	0 (0.0%)
Hong Kong	1 (1.7%)	0 (0.0%)
Ireland	1 (1.7%)	0 (0.0%)
Kenya	4 (6.8%)	1 (3.4%)
Multiple countries	1 (1.7%)	1 (3.4%)

South Africa	3 (5.1%)	0 (0.0%)
United Kingdom	1 (1.7%)	0 (0.0%)
USA	44 (75.6%)	24 (82.8%)
Population***		
Children	1 (1.7%)	1 (3.4%)
Children and adolescents	1 (1.7%)	1 (3.4%)
Adolescents/youth	2 (3.4%)	4 (13.8%)
Adolescents/youth and young adults	6 (10.2%)	0 (0.0%)
Adolescents/youth and adults	1 (1.7%)	0 (0.0%)
Young adults	1 (1.7%)	3 (10.3%)
Adults	37** (62.7%)	17 (58.6%)
Caregivers	3 (5.1%)	0 (0.0%)
Dyads		
Centers, practices, clusters, or	1 (1.7%)	2 (6.9%)
providers	5 (17.2%)	1 (3.4%)
None of the above	1 (1.7%)	0 (0.0%)
Target sample size (protocol)/Sample size (primary)		
1-100	8 (13.6%)	14 (48.3%)
101-200	9 (15.3%)	5 (17.2%)
201-300	7 (11.9%)	1 (3.4%)
301-400	10 (16.9%)	2 (6.9%)
401-500	4 (6.8%)	2 (6.9%)
501-600	2 (3.4%)	1 (3.4%)
601-700	3 (5.1%)	0 (0.0%)
701-800	3 (5.1%)	0 (0.0%)
801-900	3 (5.1%)	1 (3.4%)
901-1000	4 (6.8%)	0 (0.0%)
1000+	6 (10.2%)	3 (10.3%)
Disease area		
Behavioral and mental health	23 (39.0%)	19 (65.5%)
Cancer	2 (3.4%)	2 (6.9%)
Cardiometabolic disease	3 (5.1%)	0 (0.0%)

Infectious disease	8 (13.6%)	1 (3.4%)
Inflammatory disorders	2 (3.4%)	0 (0.0%)
Neurological disease or injury	3 (5.1%)	1 (3.4%)
Overweight and obesity	4 (6.8%)	3 (10.3%)
Pain	4 (6.8%)	1 (3.4%)
Sleep	2 (3.4%)	1 (3.4%)
Other*	7 (11.9%)	1 (3.4%)
Number of randomizations		
2	55 (93.2%)	28 (96.6%)
3	3 (5.1%)	1 (3.4%)
6	1 (1.7%)	0 (0.0%)

*Other includes: post-rehabilitation well-being, dermatopathy, health care delivery, urological disorder, vaccine uptake, intimate partner violence, nutrition, osteoarthritis, and hematological disease

** One paper focused on pregnant women which we classified as adults but might be better described as women of reproductive age

*** Because strict age-based definitions of children, adolescents, youth, and young adults varied among studies, we report the language used in the papers rather than impose our own definition of age-based groups which would not accommodate all of the papers included. We also considered distinguishing between pediatric and adult populations, but this, too, was inadequate because multiple trials targeted teens and young adults.

TABLE 2. Interventions, re-randomization criteria, and outcomes

First author, year	First stage interventions	Criterion for proceeding to 2nd stage randomization	Second and tertiary stage interventions	Primary efficacy outcome(s)	Secondary efficacy outcome(s)	Other outcome(s)
Protocol Papers						
Abuogi LL et al., 2023(15)	• Standard of Care – Routine Education & Counseling (SOC-REC) • Electronic peer navigation (eNAV)	Non-responders had a lapse in engagement, defined as either a missed clinic visit by >=14 days or HIV viral load >= 1000 copies/ml Non-responders were re-randomized to second-stage interventions	Responders **continue** their stage 1 intervention in stage 2 All non-responders were re-randomized to: • **Augment** or **switch** to standard of care with outreach and intensified counseling (SOC-OIC) • **Switch** to conditional cash transfer (CCT) for re-engagement • **Switch** to in-person peer navigation (IP-NAV)	Engagement, viral suppression	Time to return for subset of patients with lapse due to missed visits, time to viral-re-suppression for those who lapsed through an elevated viral load, retention alone, medication possession ratio, HIV RNA levels	Cost-effectiveness
Arean P et al., 2021(16)	• Video conferencing-based psychotherapy (VCP) • Message-based psychotherapy (MBP)	Non-responders failed to make a 50% reduction in PHQ-9 scores at 5-weeks Non-responders were re-randomized to second-stage interventions	Responders **continue** their stage 1 intervention in stage 2 All non-responders are re-randomized to an **augmented** treatment: • Weekly VCP+MBP • Monthly VCP+MBP	PHQ-9 (depression) and SDS	NA	Generalized Anxiety Scale (GAD-7), intervention intensity, working alliance (WAI-SR), timeliness of treatment, Experience of Care and Health Outcomes Survey (ECHO)
August GJ et al., 2016(17)	• TI-Brief: Youth-focused motivational interviewing and cognitive behavioral therapy • EP-Brief: Parent-focused use of the EcoFIT family intervention model	Non-responders were youth showing evidence of any of the following: (a) conduct behaviors in the at-risk range or higher on the Behavioral Assessment System for Children–2 (i.e., a T-score of 60 or above), or (b) impaired functioning as rated by practitioners in the School, Home, Community=Delinquency, or Behavior Towards Others domains on the CAFAS, or	Responders are **stepped down** and monitored over time for the maintenance of intervention effects Non-responders are randomized to either: • **Augment** the first stage intervention with additional content/training (TI-Extended or EP-Extended) • **Switch** to the alternative extended intervention option	NA	NA	Primary and secondary efficacy endpoints were not specified Target endpoints: Feasibility endpoints

		(c) elevated exposure to deviant peer influences on the Friendship scale (i.e., a T-score of 60 or above on either scale) Non-responders were re-randomized to second-stage interventions				
Auyeung SF et al., 2009(18)	• Escitalopram • Methylphenidate (MPH)	Non-responders were those with a Hamilton Depression Rating (HAM-D) score is >12 Non-responders were re-randomized to second-stage interventions	Responders **continue** their stage 1 intervention in stage 2 Non-responders are re-randomized to either: • Stage 1 treatment **augmented** with the other treatment • **Switched** to other treatment	Adherence to 12 weeks of IFN-alpha treatment (number of IFN-alpha treatments tolerated and study drop-out rate due to all causes)	Mood symptoms (depression, anxiety, and irritability), neurovegetative symptoms (fatigue, anorexia, altered sleep, and psychomotor slowing)	Evaluation of augmentation versus switching for non-remitters
Bahraini NH et al., 2020(19)	• Audit and Feedback (A/F) • Implementation as usual (IAU) & Follow-up	Non-responders in the A/F group: failure to complete secondary screening and comprehensive suicide risk evaluation (CSRE) for at least 80% of eligible patients A/F responders and non-responders were re-randomized to stage 2 interventions	Stage 1 IAU and follow-up sites **continue** IAU and follow-up. Stage 1 A/F sites who implemented adequately are re-randomized to either: • **Continue** A/F • **Switch** to IAU Stage 1 A/F sites who did not implement adequately are re-randomized to either: • **Continue** A/F • **Augment** A/F with facilitation	C-SSRS Screener uptake, C-SSRS uptake	Clinical performance measures that reflect key practice elements of risk identification: secondary suicide screening and the CSRE	Clinical impact endpoints, implementation (reach, sustainability, fidelity, barriers/facilitators, organizational factors)
Belzer ME et al., 2018(20)	• CPS: Cell-phone support including daily voice calls • SMS: Text-message support including personalized text reminders	Non-responders had a viral load greater than 200 copies/mL or were missing at 3 months Responders and non-responders were re-randomized to stage 2 interventions	Responders were re-randomized to either: • **Stepped Down** intervention: same mode delivered 2x/week • **Switch** to Standard of care: no further intervention Non-responders were re-randomized to either: • CPS-I: CPS **augmented** with incentives • SMS-I: SMS **augmented** with incentives	Viral load	Self-reported medication adherence	Cost-effectiveness, the 5 components of the Self-Management Model over time, barriers and facilitation
Berget C et al.,	• Two interventions focused on optimizing adherence	Adherence target: sensor wear at least 6 of 7 days on	Participants who meet both targets are not randomized to second stage	Glycemic control, quality of life	Psychosocial variables to assess quality of life	Feasibility

2019(21)	○ Developmental Demands: education on diabetes technology and problem-solving skills ○ Distress Reduction • Two interventions focused on glucose control ○ Fear of Hypoglycemia (behavioral based) ○ Remote Monitoring	average per week or <= 4 missed days in the previous 4 weeks Glucose target: sensor glucose values in the range of 70-180 mg/dl at least 60% of the time Non-responders were re-randomized to second-stage interventions	intervention Participants who fail to achieve adherence target or both targets are randomized to either **switch** or **augment** to: • No intervention • Developmental Demands • Distress Reduction Participants who fail to achieve the glucose target are randomized to either **switch** or **augment** to: • No intervention • Fear of Hypoglycemia • Remote monitoring		(health related quality of life, parents' general depression and anxiety symptoms, T1D-related distress, hypoglycemia worries)	
Buchholz SW et al., 2020(22)	• Enhanced physical activity monitor: wearable activity monitor and mobile app with goal setting and physical activity prescription • Enhanced physical activity monitor + motivational text messages	Non-responders fail to wear the Fitbit or does not have a valid day (wearing the Fitbit a minimum of 3 of 7 days in weeks 6-8, with either 10 hours of wear time or exceeding baseline step average) or does not exceed the short-term goal of 600 steps above baseline average for two of the three weeks in weeks 6 to 8 Non-responders were re-randomized to second-stage interventions	Responders **continue** their stage 1 intervention in stage 2 Non-responders are randomized to **augment** their stage 1 intervention one of two interventions: • Personal calls: motivational interviewing calls • Group meetings: structured group meetings for peer support	Physical activity (number of steps/day, minutes of moderate/vigorous physical activity/week) and aerobic fitness (V02max)	Self-reported physical activity behavior (International Physical Activity Questionnaire (IPQQ) - Long 7 Days Self-Administered), BMI, and waist circumference	Cost-effectiveness
Carr E et al., 2024(23)	• Structured exercise (EX) • Lifestyle physical activity (LPA)	Non-responders: average 7-day step count does not meet the short-term goal of 5% more than the 7-day average from the previous week for 2 of the 3 weeks in weeks 4-6 OR fails to wear their Fitbit or does not have a valid day (ie, wears the Fitbit a minimum of 3 of 7 days in weeks 4-6, with either 10 hours of wear time for that day or exceed the target step count for that day).	Responders **continue** their same stage 1 intervention for another 6 weeks. Non-responders are re-randomized to: • **Continue** stage 1 intervention • **Switch** to other intervention	Mean steps/day over 7days measured using the Fitbit Charge 4 on the non-paretic limb	Sedentary behavior (Sedentary Behavior Questionnaire), Fatigue (Fatigue Severity Scale (FSS)), Quality of Life (Stroke-Specific Quality of Life Scale (SS-QOL), EuroQol-5 Dimension-5 Levels (EQ-5D-5L)), Depression and Anxiety (Hospital Anxiety and Depression Scale (HADS)), Activities of Daily Living	Feasibility (recruitment rates, retention and adherence rates, time required for participant enrollment, recruitment site capacity), fidelity (intervention design fidelity, training fidelity, delivery fidelity, receipt fidelity, enactment fidelity)

					(Reintegration into Normal Living Index (RNLI), Physical Activity Self-Efficacy (Short Self-Efficacy for Exercise Scale (SSEE)), Cognitive Function (Cognitive Assessment Scale for Stroke Patients (CASP)), Stroke recurrence, Adverse events (death, falls)	
Comins CA et al., 2019(24)	• Decentralized treatment program (DTP) • Individualized Case Management (ICM)	Non-responders are those with viral load ≥50 copies/mL at 6 months Responders and non-responders are re-randomized in stage 2	Responders are re-randomized to: • **Switch** to standard of care (SoC) • **Continue** stage 1 intervention Non-responders are re-randomized to: • **Continue** stage 1 intervention • **Augment** stage 1 intervention with other intervention	Combined intention-to-treat outcome of retention in ART care and viral suppression at 18 months	Retention and viral suppression at 18 months among month 6 non-responders randomized to continuation of either intervention versus combined interventions, Risk factors of uncontrolled viremia and/or loss to follow-up, Durability of retention and viral suppression among 6-month responders continuing decentralized treatment or case management versus those randomized to revert to South African standard of care, Self-reported adherence and ART refill data to assess adherence across arms, Viral suppression by arms among retained participants, Loss-to-follow-up across arms, Participant reported intervention acceptability, Characterize and compare resistance	Cost-effectiveness, implementation (decentralized treatment deliveries, case management phone-based contacts, case management in-person meetings)

					across arms, Comparison of intervention cost-effectiveness according to order or intervention delivery and duration of intervention received	
Davis-Ewart L et al., 2023(25)	• Motivational Interviewing (MI): 2-session MI intervention focused on PrEP use and concomitant stimulant use or condomless anal sex • Contingency management (CM): Financial incentives for PrEP clinical evaluation and filling a PrEP prescription	Responders filled a prescription for PrEP at 3 months	Non-responders to MI were randomized to either: • Assessment only • Switch to CM Non-responders to CM were randomized to either: • Assessment only • MI	Filled a PrEP prescription	PrEP clinical evaluation, stimulant use severity, receptive and insertive anal sex, PrEP intentions, PrEP self-efficacy, PrEP acttitudes, PrEP stigma	Feasibility, experience
Doorenbos AZ et al., 2023(26)	• Acupuncture • Guided relaxation • Usual care	Responder/non-responder definition depends on pain impact score (not otherwise specified)	Non-responders are randomized to either: • **Continue** first-stage therapy or • **Switch** (first line acupuncture to guided relaxation and first line guided relaxation to acupuncture)	Pain impact score (PEG)	Opioid use, PROMIS pain interference, PROMIS sleep disturbance, PROMIS gastrointestinal constipation, Generalized Anxiety Disorder-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9), Patient's Global Impression of Change, Tobacco, Alocohol, Prescription medication, and other Substance use (TAPS) Tool, Pain Catastrophizing Scale (PCS)	Implementation
Drake CL et al., 2022(27)	• Digital Cognitive Behavioral Therapy for Insomnia (dCBT-I) • Sleep Education Control (SEC)	Non-responders: <8-point reduction in Insomnia Severity Index (ISI) score Non-responders in the dCBT-I group are re-randomized	All SEC participants and dCBT-I responders **continue** their assigned intervention Non-responders are re-randomized to: • **Switch** to clinician-led CBT-I • **Switch** to SEC	Aim 1: Insomnia Severity Index (ISI) Aim 2: Diagnosis of major depressive disorder via clinical interview using the structured clinical interview for DSM-5 disorders Aim 3: Pre-Sleep Arousal Scale's	Secondary outcomes were not explicitly defined	Surveys include the QIDS, PSASC, other clinical symptom measures; interviews include the SCID-5 module, new involvement in psychotherapy and/or pharmacotherapy

				cognitive factor (PSASC) to measure nocturnal rumination		
Edelman EJ et al., 2021(28)	• Nicotine replacement therapy (NRT) • NRT + contingency management (CM)	Responders are those whose exhaled carbon monoxide (eCO)-confirmed smoking abstinence at week 12 Non-responders in both groups are re-randomized to second-stage interventions	NRT and NRT+CM responders **continue** their stage 1 intervention in stage 2. Non-responders in the NRT only group are re-randomized to: • NRT **augmented** with CM • **Switch** to Varenicline Non-responders in the NRT+CM group are re-randomized to: • NRT + CM^{+} (**augmented** to enhanced CM) • **Switch** to Varenicline + CM	Smoking abstinence based on a negative response to "Have you smoked even a puff in the last 7 days?" confirmed with eCO ≤ 6 ppm	CD4 cell count, HIV viral load suppression, and the Veterans Aging Cohort Study (VACS) index 2.0 score	Implementation (feasibility, cost, and future implementation)
Eldridge-Smith ED et al., 2022(29)	• Positive airway pressure therapy (PAP) + sleep hygiene education • PAP + online cognitive behavioral insomnia therapy (OCBT-I)	Remission criteria is defined as an Insomnia Severity Index score <10 Non-remitters in the stage 1 PAP + OCBT-I group are re-randomized in stage 2	Stage 1 PAP + hygiene remitters have no additional treatment, but continue to complete all study assessments Stage 1 PAP + hygiene non-remitters **continue** PAP + hygiene Stage 1 PAP + OCBT-I remitters have no additional treatment but continue to complete all study assessments Stage 1 PAP + OCBT-I non-remitters are re-randomized to: • **Continue** PAP + OCBT • **Switch** to PAP + therapist-delivered CBT-I (TCBT-I)	Remission of insomnia (Insomnia Severity Index (ISI; ISI < 8))	Subjective and objective sleep data, including sleep time, sleep efficiency, fatigue ratings, PAP adherence, sleepiness ratings, sleep/wake functioning ratings, and objective daytime alertness	Global outcome measures (total wake time, general sleep quality (Pittsburgh Sleep Quality Index – PSQI), Overall daytime functioning (Functional Outcomes of Sleep Questionnaire), safety, acceptability
Fernandez ME et al., 2020(30)	AAC-Opt In (AAC-In): EHR-based point of care reminder that allows medical staff to choose when to perform Advise and Connect AAC-Opt Out (AAC-Out): EHR-based point of care that requires clinic staff to Advise and Connect tobacco users to the UTQL or to opt out.	Responders are patients who enroll in the Quitline Non-responders are patients who do not enroll in the Quitline	First stage non-responders are re-randomized to **switch** to either: • Text messaging (TM) • Continued AAC (CO) Non-responders to second-stage TM are randomized to either: • **Continue** text message (TM-Cont) • **Augment** text message with MAPS (TM+MAPS): continued text messages with two brief phone calls with patient	Reach (proportion of tobacco users who enroll in UTQL treatment), impact (the product of reach and efficacy where efficacy is patient abstinence status at 12 months following patient's initial encounter among those enrolled in the UTQL)	NA	Implementation

			navigators/health educators trained in MAPS counseling			
Flynn D et al., 2018(31)	• Standard rehabilitative care (SRC) • Complementary and integrative health therapies (CIH)	Non-responders are those who experienced a Pain Impact Score improvement of <3 points Non-responders are re-randomized in stage 2	Responders **continue** their stage 1 intervention in stage 2. Non-responders are re-randomized to: • **Augment** their stage 1 treatment with the other treatment • **Switch** to the other treatment	Pain impact score	PROMIS measures (global health, depressive symptoms, anxiety, emotional distress (anger), sleep disturbance, and fatigue), functional capacity tests (Modified Naughton treadmill test, floor-waist lift test, waist-shoulder lift test, 40-ft carry test), and force readiness (Military Readiness Category status)	Pain and function surveys, biological measures
Fox CK et al., 2024(32)	• Lifestyle therapy (LST) for 12 weeks with added phentermine (Phen) for an additional 12 weeks if BMI did not decrease by ≥5% • LST for 24 weeks with added phentermine (Phen) for an additional 12 weeks if BMI did not decrease by ≥5%	Those with the added 12 weeks of Phen who did not decrease their BMI by ≥5% were re-randomized in stage 2	Those in the LST x 12 weeks group who decreased their BMI by ≥5% at 12 weeks **continued** LST for an additional 36 weeks. Those in the LST x 12 group who did not decrease their BMI by ≥5% at 12 weeks added Phen for an additional 12 weeks. After the Phen x 12 weeks, those who decreased their BMI by ≥5% **continue** Phen + LST for 24 weeks. For those who did not decrease their BMI by ≥5% after Phen x 12 weeks, they were re-randomized to: • **Augment** with topiramate (TPX) for 24 weeks (i.e. TPX + Phen + LST x 24 weeks • **Switch** to TPX + Placebo + LST x 24 weeks Those in the LST x 24 weeks group who decreased their BMI by ≥5% at 12 weeks **continued** LST for an additional 24 weeks. Those in the LST x 24 group who did not decrease their BMI by ≥5% at 12 weeks added Phen for an additional 12 weeks. After the Phen x 12 weeks, those who decreased their BMI by ≥5% **continue** Phen + LST for 12 weeks. For those who	Percent change in BMI from baseline measured 48 weeks after baseline	Changes in body composition, cardiometabolic profile (blood pressure, heart rate, lipids, glucose, hemoglobin A1c, ALT, AST), and quality of life (IWQOL-Kids) between baseline and 48 weeks	Safety, biopsychosocial moderators

			did not decrease their BMI by ≥5% after Phen x 12 weeks, they were re-randomized to: • **Augment** with topiramate (TPX) for 12 weeks (i.e. TPX + Phen + LST x 12 weeks • **Switch** to TPX + Placebo + LST x 12 weeks			
Fritz JM et al., 2020(33)	• Physical therapy (PT) • Move 2 health (M2H)	An improvement from a baseline of ≥7 T score points on the pain interference computer-adapted test (PI-CAT) is required to be considered a responder Treatment non-responders are re-randomized in stage 2	Treatment responders **continue** up to 2 more sessions of their stage 1 treatment for step-down care. Treatment non-responders are re-randomized to: • **Augment** their stage 1 treatment with the other treatment • **Switch** to mindfulness-oriented recovery enhancement (MORE)	Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference computer-adapted test (PI-CAT)	PROMIS physical function CAT (PF-CAT), PROMIS CAT assessments of health domains relevant to chronic lower back pain, including sleep disturbance, depression, and anxiety, Patient Acceptable Symptom State (PASS), European Quality of Life 5-Dimension Instrument (EQ-5D), Defense and Veterans Pain Rating Scale (DVPRS), Pain Intensity, Enjoyment of Life, and General Activity Three-Item Scale (PEG-3), Perceived readiness for duty	Cost-effectiveness, feasibility
Fu SS et al., 2017(34)	• Tobacco Longitudinal Care (TLC): Telephone coaching for 4 weeks • TLC for 8 weeks	Non-responders: any smoking, even just a puff, during the 7 days preceding the data of assessment Responder: No smoking during the 7 days preceding the date of assessment	Non-responders are re-randomized to either: • **Continue** TLC • **Augment** TLC+MTM (Medication Therapy Management) Responders are re-randomized to either: • **Continue** TLC • **Step down** to TLC-Quarterly: Less intensive TLC	6-month prolonged abstinence measured 18 months after the beginning of TLC	30- and 7- day point prevalent abstinence, number of quit attempts, satisfaction with study treatment, self-assessment of cancer risk, cigarettes per day	Other measures include: Physical health, mental health and alcohol use, regulatory focus, smoking history, social support for cessation, smoking cessation-related beliefs and stress, treatment utilization and satisfaction, risk-perception for lung cancer, lung cancer screening outcomes

Germeroth LJ et al., 2019(35)	• Prenatal lifestyle intervention (HABITpreg) • Treatment as usual (TAUpreg)	This is a non-restricted SMART, meaning the second randomization is not influenced by participants meeting specified criteria, and all women are re-randomized prior to delivery	All participants are re-randomized to **switch** to: • Postpartum lifestyle intervention (HABITpost) • Treatment as usual (TAUpost)	Weight at 12 months postpartum	Cardiometabolic health indicators and psychosocial well-being (insulin resistance, lipids, inflammation markers), depressive symptoms (CES-D, EPDS), perceived stress (PSS scale), sleep quality (PSQI), dietary intake (Nutrition Data System for Research), physical activity)	NA
Hassett AL et al., 2023(36)	• Mindfulness-Based Stress Reduction (MBSR) • Physical Therapy and Exercise (PT) • Acupressure m Health self-management • Duloxetine	Non-responders: no or minimal improvement in pain (PGIC >=2) Non-responders to stage 1 interventions are re-randomized in stage 2	Non-responders are re-randomized to **switch** to one of the first-stage interventions they did not initially receive. Responders do not receive additional intervention	PROMIS Pain interference short form score at T3 taken at the conclusion of Treatment 1	NA	Predictive endpoints for phenotyping, mechanistic endpoints for phenotyping, causal analysis endpoints
Hibbard JC et al., 2018(37)	• CO2 laser + non-surgical medical therapy (CO2) • Pulse-dye laser + non-surgical medical therapy (PDL) • Non-surgical medical therapy alone (MED)	All participants are re-randomized, independent of on-going response	Stage 2 and 3 interventions are the same as those in Stage 1. Allowable treatment sequences (including stage 1) are to **continue** or **switch** as follows: • CO2-CO2-MED • CO2-MED-CO2 • CO2-MED-PDL • CO2-PDL-MED • MED-CO2-CO2 • MED-CO2-PDL • MED-PDL-CO2 • MED-PDL-PDL • PDL-CO2-MED • PDL-MED-CO2 • PDL-MED-PDL • PDL-PDL-MED	Vancouver Scar Score	Quality of life, alternative scar scores	NA
Inwani I et al., 2017(38)	• Standard referral to receive HIV care and treatment services • Standard referral + SMS reminder to seek care	Non-responders: Not enrolled in care within 2 weeks of the initial intervention Non-responders to stage 1 interventions are re-randomized in stage 2	Responders receive no further interventions Non-responders are randomized to **switch** to either: • SMS reminder to seek care • Unconditional cash transfer to overcome structural barriers to care	The primary end point for comparisons of recruitment and testing strategies is newly diagnosed HIV infection.	NA	Cost-effectiveness, linkage to care, retention and adherence, HIV prevention-related endpoints, linkage to care

Jain S et al., 2023(39)	• Infliximab • Steroids • Anakinra	Non-responders meet at least one of the following: fever, persistent or worsening inflammation, or organ damage	Responders receive no further intervention Non-responders are randomized to **switch** to one of the two treatments not previously assigned	Rate of randomization to secondary treatment	NA	Safety
Johnson JE et al., 2018(40)	• Continue Enhanced implementation as usual (EIAU) • EIAU + Low-Intensity Coaching and Feedback (LICF)	Non-responders to EIAU+LICF: Either no ROSE intervention in 3 months and none planned or less than 75% fidelity to ROSE core elements	Those randomized to continue EIAU in stage 1 receive no further intervention Non-responders to EIAU+LICF are re-randomized to either: • **Continue** EIAU + LICF • **Augment** to EIAU + LICF + High intensity coaching and feedback (HICF) Responders to EIAU+LICF **continue** with EIAU+LICF	Percent sustainment of core program elements at each timepoint	PPD rates over time at each clinic	Reach, cost-effectiveness, implementation
Kilbourne AM et al., 2014(41)	• (REP) with external facilitation (REP+EF) • REP with internal and external facilitation (REP+EF/IF)	Non-responders were sites with <50% of patients receiving >=3 EBP sessions	Non-responders to REP+EF are randomized to either: • **Continue** REP+EF • **Augment** to REP+EF/IF Non-responders to REP+EF/IF **continue** REP+EF/IF Responders do not receive additional intervention	Mental health-related quality of life	Receipt of LG sessions, mood symptoms, implementation costs, and organizational change	Implementation, cost-effectiveness, organizational and provider factors
Kopelowicz A et al., 2023(42)	• Tomando control (TC) intervention led either by a community health worker or promotore (TC-promotore) • TC led by a registered nurse (TC-Nurse)	Non-responders: 50% gain over baseline on the Summary of Diabetes Self-Care Activities (SDSCA)	Non-responders are randomized to either: • First stage intervention **augmented** by family-focused TC • **Switch** to Multifamily Group (MFG) Responders **continue** their first-stage intervention	Difference in the SDSCA between the groups at 3, 6, and 12 months after baseline	Diabetes self-efficacy, diabetes knowledge, degree of family support, collaborative goal setting, treatment session attendance, glycemic control	Attendance, vitals
Kor PP et al., 2023(43)	• Behavioral activation (BA) - a psychological intervention that encourages engagement in meaningful, healthful, and enjoyable activities to improve mood • Mindfulness practice (MP) - a psychosocial intervention focused on increasing mindfulness through exercises like meditation, mindful	Non-responders are those with a reduction in PHQ-9 scores of less than 50% Non-responders are re-randomized in the second stage	Responders proceed to monthly booster sessions. Non-responders are re-randomized to: • **Augment** their stage 1 intervention with an additional self-efficacy enhancing strategy • **Switch** to the other intervention	Depressive symptoms (PHQ-9)	Perceived caregiving stress, positive aspects of caregiving (PAC), sleep quality, and health-related quality of life (HRQoL)	Engagement in meaningful activities and level of mindfulness (patient logbooks and Five Facet Mindfulness Questionnaire)

	breathing, and body scanning					
Levy R et al., 2019(44)	• Interpersonal psychotherapy (IPT) • Fluoxetine (F)	Non-responders are those who continue to meet MINI criteria for MDD and/or PTSD diagnosis	Non-responders are randomized to either: • **Switch** to the other first-stage treatment • Combination of first-stage treatments (**augment**)	Major Depressive Disorder (MDD) and Posttraumatic Stress Disorder (PTSD) using MINI-MDD and MINI-PTSSD modules	Accessibility; affordability; domestic violence, alcohol, drugs, and trauma; physical health; emotional reactivity; social support	Economic, implementation
Li X et al., 2021(45)	• Olanzapine • Risperidone • Amisulpride • Aripiprazole • Perphenazine (a first-generation antipsychotic)	Response is defined as a ≥40% reduction in Positive and Negative Syndrome Scale (PANSS) total score Stage 1 non-responders (or those with intolerable side effects) are re-randomized to the second-stage intervention Stage 2 non-responders are re-randomized to the third-stage intervention	Stage 1 responders **continue** their original treatment Phase 1 non-responders are re-randomized to **switch** to one of the following three treatments (no one is assigned to the same drug as phase 1): • Olanzapine • Amisulpride • Clozapine (which is often reserved for treatment-resistant schizophrenia) Phase 2 clozapine non-responders are re-randomized to: • **Continue** clozapine (clozapine extended treatment) • **Switch** to modified electroconvulsive therapy (MECT) add-on therapy Phase 2 non-clozapine non-responders are re-randomized to: • **Switch** to clozapine • **Switch** to another SGA not previously used in phase 1 or 2	Treatment phase: treatment efficacy rate, which is defined as a 40% reduction or more of the total score in the Positive and Negative Syndrome Scale (PANSS) Naturalistic follow-up phase: time to all-cause treatment failure, marked by its discontinuation, and all-cause discontinuation is defined as discontinuing for any reasons (including poor efficacy, intolerance of adverse reactions, poor compliance et al.)	Secondary outcomes were not specified	Clinician and functional assessments, neurocognitive assessments, neuroimaging, pharmacoeconomic and cost-effectiveness assessments
Lion KC et al., 2023(46)	• Web-based education modules • Mobile video interpreting access	Providers with interpreter use in the top tertile (within strategy) will remain with the original strategy; those in the bottom two tertiles will be re-randomized	Providers in the top tertile remain in their original intervention Providers in the bottom two tertiles were randomized to either: • **Continue** with their original intervention • Receive both interventions (combination, **augment)**	Interpreter use	Patient comprehension, determined by comparing patient-reported to provider-documented visit diagnosis	Cost-effectiveness
Liu H et al., 2021(47)	• Monthly Brief Contact Interventions (BCIs)	Participants initially randomized to monthly	For those initially assigned to monthly BCIs:	Trajectories of suicide risk (suicide	Trajectories of suicide risk from 3-month to	Implementation and service outcomes

	• Weekly BCIs	BICs will be rerandomized if their suicide risk increases, while participants initially randomized to weekly BCIs will be rerandomized if their suicide risk decreases. Suicide risk is defined as the probability of an individual's death by suicide over a given time interval reflected by the intensity and frequency of suicide ideation, suicide plan, suicide preparation and suicide attempts. Suicide risk will be evaluated by the Beck Suicide Ideation Scale-Chinese Version (BSI-CV) and the suicidality module of the Mini-International Neuropsychiatric Interview (M.I.N.I-Suicidality)	• If suicide risk increases, they are randomized to **augment** to either: ○ Weekly BCIs ○ Biweekly BCIs • If suicide risk is decreases or remains the same, **continue** with monthly BCIs For those initially assigned to weekly BCIs • If suicide risk increases or remains the same, **continue** weekly BCIs • If suicide risk decreases, they are re-randomized to **augment** to either: ○ Monthly BCIs ○ Biweekly BCIs	ideation and suicidality) from baseline to 3-month and 12-month post-discharge	12-month post-discharge, trajectories of social connectedness and social support from baseline to 3-month and 12-month post-discharge	
Markland AD et al., 2023(48)	• MyHealtheBladder: Interactive mHealth treatment for urinary incontinence (UI) • VA Video Connect (VVC): single virtual visit with a UI clinician	International Consultation on Incontinence Questionnaire – Urinary Incontinence Short From (ICIQ-UI) < 2.52 at 8 weeks	Responders **continue** their initial treatment Non-responders are re-randomized to either: • **Continue** first-stage treatment • **Switch** or **augment** to VA Video Connect Booster Visit	International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF)	Other lower urinary tract symptoms, impact on quality of life, adherence to the pelvic floor muscle exercises, retention rates for program completion, satisfaction with treatment, perceptions of improvement, costs of incontinence care, miles saved, usability of the mHealth app, and adaptive behaviors related to UI	Cost, usability, implementation feasibility (miles saved)
Micheletti RG et al., 2020(49)	• Azathioprine • Colchicine • Dapsone	Non-response: Patients who subsequently discontinued the study drug during the 6 months of the first stage of the study or the follow-up period (month 6 to month 12) because of any one of the following endpoints per protocol-defined	Responders **continue** initial treatment Non-responders are re-randomized to **switch** to one of the other two drugs not assigned in the first stage	Proportion of participants with a response to therapy at month 6 of the pooled study Stages 1 and 2	Proportion of patients with complete response to therapy (no new lesions within the preceding 3 months) at months 3, 6, and 12; proportion of patients with significant response to therapy (three or fewer	NA

		definitions: a lack of response or failure, a relapse (month 6 to month 12), or a side effect necessitating drug discontinuation 2. Patients with a history of significant intolerance, allergy, or serious adverse events to one of the study medications, deficit in glucose-6-phosphate dehydrogenase (G6PD) or thiopurine methyltransferase (TPMT) or history of hemolytic anemia, or who failed to respond (according to the study definition) to one of the study drugs prior to screening			minimally symptomatic lesions per flare, with no more than one flare per month in the preceding 3 months) at months 3, 6, and 12; time to achieve complete or significant response; time to vasculitis flare for patients who achieved a complete or significant response before month 6 but subsequently relapsed; frequency of vasculitis flares/new lesions compared to baseline; physicians' global assessments of response; patients' global assessments of response; prednisone use during the study period; Skindex29 score at months 1, 3, 6, 9, and 12 (Captures skin-related pain, pruritus, discomfort); patient-reported outcomes/disease burden at months 1, 3, 6, 9, and 12; response according to patient and disease characteristics; grading of standardized photographs by blinded investigators"	
Nelson B et al., 2018(50)	Open label support and problem solving (SPS) will be provided to all participants. Responders continue SPS monthly until month 12 Non-responders to SPS will be randomized to either: • Cognitive behavior case	Response is defined as: The Global Rating Scale or the Frequency score need to be less than 3 for all of the four positive symptoms (unusual thought content, non-bizarre ideas, perceptual abnormalities	Responders will **continue** or **switch** to SPS monthly until month 12 CBCM non-responders are re-randomized to: • **Augment** with SSRI • **Augment** with Placebo	6-month Global Functioning Social and Role Scale	Secondary outcomes were not distinguished	Safety, psychopathology, functioning and quality of life, biological, neurocognition, neuroimaging, cerebrospinal fluid

	management (CBCM) • SPS	and disorganized speech) and there is an improvement of at least 5 points in Social and Occupational Functioning Assessment Scale (SOFAS) compared with baseline or the SOFAS score is at least 70 Non-responders are re-randomized	SPS non-responders are re-randomized to: • **Switch** to CBCM + SSRI • **Switch** to CBCM + placebo			
O'Keefe VM et al., 2019(51)	• New Hope + Optimized Case Management (OCM): A two-to-four-hour session with an Apache Community Mental Health Specialist focused on reducing immediate suicide risk • OCM alone: Monthly case management visits by independent evaluators who connect youth to behavioral health or community services and administer suicide risk assessments.	All participants are re-randomized regardless of first-stage intervention or response to first-stage intervention	Everyone was re-randomized to: • **Switch** to Elders' Resilience + OCM: A two-to-four hour session with Apache Elders aimed to promote resilience • **Continue** or **step down** to OCM: same as the first stage	Suicidal ideation (SIQ/SIQ-JR) and resilience (modified Resiliency Scales for Children and Adolescents (RSEA))	Depressive and anxiety symptoms, impulsivity, self-efficacy and communal mastery, importance of following AI values and cultural practices, self-esteem, hope, substance use, and a subset of local WMAT generated items relating to changes observed among youth who have previously received New Hope or Elders' Resilience interventions	NA
Osilla KC et al., 2023(52)	• Partners Connect: a four-session web-based intervention that utilizes CRAFT principles that was designed to help concerned partners (CPs) increase self-care and improve their communication skills regarding their service members (SMs) drinking. • Gottman Resources: The Gottman Institute website was developed based on decades of observational research with couples, showing how negative communication and emotional flooding are highly predictive of poorer family and individual well-being	Non-responders are those where the SM does not access PNF or click "done"	Partners Connect non-responders are re-randomized to: • **Switch** to CRAFT Workbook: The CRAFT workbook helps us evaluate what combination of self-directed materials could help dyads who may not otherwise seek treatment • **Switch** to Phone-CRAFT: The phone-based CRAFT intervention consists of six individual sessions with a CRAFT-trained clinician reviewing the CRAFT workbook content. Gottman Resources non-responders are re-randomized to: • **Switch** to Partners Connect	CP primary outcome: Drinking (number of drinks per week in the past month) SP primary outcome: help-seeking through response to the SMART intervention (clicking "done" at the end of the PNF program)	CP outcomes: mental health symptoms (anxiety/depression), communication via the Communication Patterns Questionnaire, social support from the Medical Outcomes Study Social Support Scale SM outcomes: additional help seeking behaviors (preparatory behaviors, intentions, or actual care initiation)	CP communication, CP drinking, SM perceived drinking norms

			• **Switch** to CRAFT Workbook			
Peter SC et al., 2023(53)	• Brief Motivational Interviewing + Substance Free Reinforcement + Mindfulness Sessions (BSM): weekly discussion centered around increasing engagement in substance-free activities that are enjoyable and/or consistent with the individual's goals or values • Contingency Management (CM): a behavioral treatment where prizes or vouchers are provided to patients based upon proof of a desired behavior such as abstinence or adherence to a medication	A participant is considered non-adherent if they meet either of the following criteria: • Missed a physician visit for buprenorphine-naloxone treatment. • Buprenorphine is absent in their urine toxicology screen. Non-adherent participants are re-randomized in stage 2	Participants who are adherent will **continue** their initial treatment for up to 6 months Non-adherent participants are re-randomized to: • **Augment** their original intervention with the other treatment (combination of the two) for 6 months • **Switch** to the other treatment for 6 months	Medication adherence	Secondary outcomes were not distinguished	Behavioral economic-related variables, mental health measures
Peterson BS et al., 2021(54)	• Fluoxetine: SSRI medication targeting the biological mechanisms of anxiety by increasing serotonin levels • Cognitive behavioral therapy (CBT): focuses on exposure therapy, coping skills development, and cognitive restructuring	Criteria for remission includes: (a) a youth screen for child anxiety related disorders (SCARED-41) score less than diagnostic threshold for any single anxiety disorder, together with (b) a total youth SCARED-41 score < 10, and (c) a score of ≤8 on the CAIS (Child Anxiety Impact Scale). Non-remitters were re-randomized in the second stage	Remitters **continue** their stage 1 treatment Non-remitters are re-randomized to: • **Continue** their stage 1 treatment for 12 weeks • **Augment** their stage 1 treatment with the other treatment for 12 weeks	Self-report score on the 41-item youth SCARED (Screen for Child Anxiety Related Disorders)	Parent ratings of anxiety symptom severity on the Youth SCAR ED-41, and parent and youth ratings on the CAIS (Child Anxiety Impact Scale)	Patient-centered outcomes; social, family, and school functioning; mental health and emotional regulation; sleep and side effects; treatment experience and acceptability
Pfammatter AF et al., 2019(55)	• mHealth SMART app (App): app used to record dietary intake and to monitor graphical feedback that displays their dietary intake, physical activity, and weight relative to daily and long-term goals • mHealth SMART app + coaching (App + C): diet and activity coaching are provided together with the app.	If the average weekly weight loss is found to be <0.5 pounds at the 2, 4, or 8 week time point, the participant will be classified as a non-responder Non-responders are re-randomized in the second stage	Responders **continue** their stage 1 intervention Non-responders are re-randomized to: • Modestly step up (**augment**) their initial treatment with texts (+ T) • Vigorously step up (**augment**) their initial treatment with texts and coaching for the	Change in weight (kilograms) from baseline to 6 months	Secondary outcomes were not distinguished	Cost-effectiveness, self-efficacy, autonomous motivation

	Coaching calls last approximately 10-15 min and include feedback and problem solving delivered within a motivational interviewing (MI) framework		stage 1 App group (App + T + C) and with texts and meal replacement for the stage 1 app + C group (App + T + C + M)			
Quanbeck A et al., 2020(56)	• EM/AF: Engagement meetings and audit and feedback which included educational information and engagement through in-person and webinar delivery and performance feedback on opioid prescribing practices • EM/AF + PF: Engagement meetings and audit feedback plus practice facilitation defined as EM/AF + an external facilitator focused improving clinic-level opioid prescribing workflows	All clinics are re-randomized regardless of first-stage intervention or response to first-stage intervention	First stage EM/AF clinics were re-randomized to either: • **Continue** EM/AF only • **Augment** EM/AF + PPC First stage EM/AF + PF clinics were re-randomized to either • **Continue** EM/AF + PF • **Augment** EM/AF + PF + PPC PPC is prescriber peer consulting, defined as quarterly access to physician or pharmacist experts experienced in opioid management	Average of morphine-milligram equivalent (MME) dose per day per opioid patient, calculated over a 3-month period	NA	Cost estimates of the 4 sequences, implementation outcomes, adoption and reach metrics
Rabin BA et al., 2023(57)	• Standard of care (SOC; control group): patients receive routine healthcare services at their Federally Qualified Health Center (FQHC). Includes routine immunization efforts, annual physical exams, and preventive screenings • mHealth Outreach (intervention group – lower intensity): patients receive mobile health (mHealth) messages (text messages and automated voice calls). Messages are culturally tailored and linguistically appropriate	Non-response is defined as not being up to data on COVID-19 vaccination OR having at least one outstanding preventive service need Non-responders are re-randomized in stage 2	Responders **continue** their stage 1 intervention Non-responders in the mHealth group are re-randomized to: • **Continue** mHealth outreach • **Augment** mHealth outreach with care coordination: the deliberate organization of patient care activities between two or more participants involved in a patient's care to facilitate the appropriate delivery of health care services Non-responders in the SOC group are re-randomized to: • **Switch** to mHealth outreach • **Switch** to mHealth outreach + care coordination	COVID-19 vaccine completion	Increase in preventive service engagement, increase in vaccine confidence	Implementation, reach, adoption, and maintenance
Sabri B et al., 2021(58)	• myPlan app: a safety decision and planning tool delivered through a free and secure web-based app. • Usual care control	Non-responders: women who report both no improvement in safety (i.e., significant reduction in severity and frequency of IPV) and empowerment scores (i.e., significant improvement in	Responders **continue** their original intervention. Non-responders in both groups are re-randomized to: • **Switch** to safety and empowerment strategies delivered via text	Severity and frequency of IPV (Revised Conflict Tactics Scale (CTS2)), empowerment (Personal Progress Scale-Revised (PPS-R), MOVERS scale)	Depression (PHQ-9), Post-traumatic stress disorder (PTSD)	NA

		empowerment) from baseline to 3 months Non-responders are re-randomized to second stage interventions	• **Switch** to combination of text and phone calls with trained advocates			
Schlechter CR et al., 2023(59)	• Single Text Message (TM1) • Multiple Text Message (TM+)	Non-responders: No enrollment in evidence-based interventions, including improving diet and nutrition, increasing physical activity, and behavioral strategies such as goal setting and self-monitoring	Non-responders to TM1 are randomized to either: • **Step down** to no additional text messages • **Switch** to Motivation and Problem Solving Counselling (MAPS) Non-responders to TM+ are randomized to either • **Continue** TM+ • **Augment** TM+ and MAPS Responders receive no further intervention	NA	NA	Feasibility, acceptability
Skolasky RL et al., 2020(60)	• Physical Therapy (PT) • Cognitive Behavioral Therapy (CBT)	Non-responders: Not experiencing at least 50% reduction in pain-related disability	Non-responders to PT are randomized to either: • **Switch** to CBT • **Switch** to Mindfulness-Oriented Recovery Enhancement (MORE) Non-responders to CBT are randomized to either: • **Switch** to PT • **Switch** to MORE Responders **continue** first-stage therapy	Disability (Oswestry Disability Index), pain intensity (Numerical Pain Rating Scale)	General health (PROMIS-29 SF), long term opioid use, health care utilization	Implementation, physical adverse effects, risk for poor outcomes
Smith SK et al., 2021(61)	• Cancer Distress Coach (CaDC) App: a mobile mHealth intervention based on the PTSD Coach app. Includes educational content, self-guided coping strategies, symptom tracking, and access to resources • Usual care control: standard mental health services available to all cancer patients at their institution	Non-responders: <5-point reduction in PTSD symptom severity score Non-responders are re-randomized to second stage interventions	Responders **continue** their initial intervention Non-responders in the CaDC group are re-randomized to: • **Augment** CaDC with mCoaching: virtual clinician support • **Switch** to mHealth cognitive behavioral therapy (mCBT): HCT-specific telephone administered CBT protocol Non-responders in the usual care control group are re-randomized to:	PTSD Checklist for DSM5 (PCL5) with items modified to key on cancer-related symptoms, as has been validated in the HCT population	Cancer-related distress, depression, and anxiety (Distress Thermometer v.2018); general perceptions of health (NIH PROMIS Global QOL); depression, anxiety, and pain interference (PROMIS 8-item instruments); how capable one feels in managing symptoms and performing health-related tasks (Self-	Participant satisfaction, adherence

			• **Switch** to CaDC + mCoaching • **Switch** to mCBT		efficacy for Managing Chronic Disease Scale); post-intervention survey includes questions regarding the participant's study experience (i.e., perceived helpfulness and satisfaction) to inform future improvements to the protocol and/or programs; CaDC clickstream activity (i.e., usage)	
Sripada RK et al., 2023(62)	• Prolonged Exposure for Primary Care (PE-PC): 30-45 minute sessions of in-vivo and imaginal exposure • Clinician Support (CS) PTSD Coach: incorporates evidence-based assessment, psychoeducation, cognitive behavioral therapy and self-management strategies that are customizable to the user	Early responders are participants who experience at least a 15-point symptom reduction or have a PCL-5 score <29 Slow responders are re-randomized to second stage interventions	Early responders to PE-PC **step down** to every other week Early responders to CS PTSD Coach **step down** to self-managed (SM) PTSD Coach Slow responders in both groups are re-randomized to: • **Continue** first line treatment • **Step up** to Full PE: in-vivo exposure, imaginal exposure to the trauma memory, and facilitated emotional processing of the trauma	3-month score on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)	PCL-5, a 20-item self-report measure of PTSD symptoms as defined by the DSM-5	Process evaluation, fidelity measures, risk assessment, cost-effectiveness
Tamura K et al., 2020(63)	• Tailored-to-place message (TPM) • Standard remote messaging (SRM)	Non-responders: those who do not meet the PA goal of 10,000 steps/day after 3 months to more intensive treatment	Responders **continue** initial intervention Non-responders to TPM are re-randomized to either: • **Augment** TPM + face-to-face coaching • **Step up** TPM with greater frequency Non-responders to SRM are re-randomized to either: • **Augment** SRM + face-to-face coaching • **Switch** to TPM	NA	NA	Primary and secondary outcomes were not distinguished. Survey data (health history, access and the behavioral, psychosocial, cultural, and perceived environmental factors that may influence the impact of intervention), neighborhood environment measures, mHealth data (step count,

						minutes of vigorous activity, sleep time), clinical measures
van Heerden A et al., 2023(64)	• Best Clinic Practices (Standard of Care – SOC): Welcome back service (friendly providers, SMS, adherence support) and optimized ART refills • Best Clinic Practices + Lottery Incentives: Conditional lottery incentives, welcome back service, and optimized ART refills	Responders are participants who are virally suppressed and engaged in care at month 6 Non-responders are participants with a detectable viral load or not engaged in care/lost to follow-up (LTFU) Non-responders are re-randomized to second stage interventions	Responders **continue** their original intervention Non-responders are re-randomized to: • **Continue** original intervention • **Switch** to smart lockers (Pele boxes): decentralized ART refills and monitoring and adherence support • **Switch** to home-delivery and monitoring of ART: Home ART refills and monitoring and adherence support	Viral suppression at 18 months	Retention in care, time to ART initiation	Qualitative preferences of clients and providers, cost-effectiveness and economic measures
Velloza J et al., 2022(65)	• Two-way SMS: Weekly SMS messages with follow-up if participants respond that they are not feeling well or fail to respond • WhatsApp support group: Virtual peer support groups moderated by a staff facilitator and "PrEP Ambassador"	Responders: Dried blood spot (DBS) tenofovir diphosphate (TFV-DP) levels >= 500 fmol/punch at month 2 Non-responders: TFV-DP levels <500 fmol/punch or have missed PrEP refills	Responders **continue** first-stage treatment Non-responders are re-randomized to either: • First-stage intervention **augmented** by quarterly drug-level feedback counseling where participants get personalized adherence feedback • First-stage intervention **augmented** by intensive problem-focused counseling sessions during which adherence barriers and facilitators are discussed	PrEP adherence measured as DBS TFV-DP drug concentration >=700 fmol/punch at nine monhts	PrEP adherence, analyzed as continuous TFV-DP levels as well as in a five-category variable (below the limit of quantification [BLQ], BLQ–349 fmol/punch, 350–699 fmol/punch, 700–1249 fmol/punch, and >=1250 fmol/punch), shorter-term impact of interventions on TFV-DP levels at two months	Acceptability and feasibility of interventions, adherence, and discontinuation
Walton MA et al., 2023(66)	• TM: Tailored text messages automatically sent 2/day for 4 weeks • HC: Health coach telephone call 1/week for 4 weeks	Responder: Not reporting any binge drinking or aggression in weeks 3 and 4 Non-responders: Reporting binge drinking or aggression in weeks 3 or 4, those missing survey data in weeks 3 or 4	Responders were re-randomized to either **continue** condition or **stepped down**: • Responders to TM or HC who are randomized to the stepped down condition receive a brochure Non-responders were re-randomized to either **continue** condition or **stepped-up** condition • Non-responders to TM who are randomized to the **stepped-up** condition receive	Alcohol consumption and violence, both using 30-day timeline follow back (TLFB) interview	Alcohol-related consequences (modified Brief Young Adult Alcohol Consequences Questionnaire (B-YAACQ)), violence consequences	Other drug use (ASSIST-Lite) and victimization (past 30-day TLFB)

			HC calls • Non-responders to HC who are randomized to the **stepped-up** condition receive the intensified HC condition (HCs send supportive text messages between calls)			
Wan Y et al., 2023(67)	• Monthly Online Collaborative Care (WeChat Mini Program-based Intervention: a digital platform designed for dementia care • Monthly Offline Collaborative Care (Traditional Face-to-Face Home Visits): care provided in person via home visits by healthcare providers	Responders are those who experience improvement on patients' quality of life AND reduction of caregivers' burden. An improvement in quality of life for patients with dementia (response) is defined as scoring 10 points higher on the QOL-AD at the checkpoint than at the baseline. A reduction in caregivers' burden (response) is defined as a decrease in burden severity of at least one level on the Zarit Burden Interview (ZBI) compared with baseline, such as from severe to mild or from moderate to mild. Responders are re-randomized to stage 2 interventions	Non-responders **step up** their stage 1 intervention to biweekly Responders are re-randomized to: • **Continue** their stage 1 intervention monthly • **Step down** their stage 1 intervention to bimonthly	Proportion of patients demonstrating an improvement in quality of life and the proportion of caregivers exhibiting a reduction in caregiver burden (improvement in quality of life (10 points higher on QOL-AD), reduction in caregiver burden (decrease in burden severity of at least one level on ABI compared to baseline))	Cost-effectiveness of collaborative care, cognitive change of patients, change in activities of daily living of patients with dementia, change in the number of behavioural and psychological symptoms of patients with dementia, change in depressive symptoms of patients with dementia and caregivers, change in anxiety symptoms of caregivers	Feasibility
Wilroy J et al., 2023(68)	• Asynchronous Movement-to-Music (M2M) for 3 weeks • Asynchronous M2M for 6 weeks	Non-responders <95% of video watch minutes	Non-responders are randomized to either: • **Augmentation** of Asynchronous M2M with Individual Behavioral Coaching (IBC) • **Switch** to M2M live Responders **continue** asynchronous M2M	NA	NA	Feasibility (primary aim), acceptability (secondary aim), exercise adherence, physical activity, physiological outcomes, psychosocial outcomes, app quality and usability
Windsor L et al., 2022(69)	• Navigation Services (NS) • Digital Brochure (DB)	Non-responders: Failure to complete COVID-19 testing with 7 days after the first intervention session	NS responders are randomized to either: • **Continue** NS • **Switch** to Critical Dialogue (CD) NS non-responders are randomized to	Completion of at least one COVID-19 test within 1 week of the first intervention session	Adherence to the prevention guidelines in the past month (Multi-ethnic Study of Atherosclerosis (MESA))	Process (intervention fidelity, quality assurance, and facilitator competence),

			either: • **Continue** NS • **Switch** to Brief Counseling (BC) DB responders are randomized to either: • **Continue** DB • **Switch** to BC DB non-responders are randomized to either: • **Continue** DB • **Switch** to CD			integrity assessments, predictor and outcome standardized measures to assess social determinants of health, demographics, COVID-19 risk (including comorbidities, exposure to SARS-CoV-2, adherence to prevention guidelines), attitudes about COVID-19 testing, health and social services used, knowledge about COVID-19, attitudes about COVID-19 vaccines and booster shots, mental health, protective factors and barriers to health care, confidence in government, and the healthcare system
Yan X et al., 2022(70)	• App + relaxed • App + stringent	Non-responders to stage 1 intervention: if randomized to App + relaxed in stage 1, failure to engage with the app at least once; if randomized to App + stringent in stage 1, failure to engage with the app at least twice Non-responders to stage 2 intervention: if randomized to App + relaxed in stage 1, failure to engage with the app at least twice; if randomized to App + stringent in stage 1, failure to engage with the app at least three times"	Stage 1 responders **continue** their original intervention Non-responders to App + relaxed in Stage 1 are randomized to either: • **Continue** App + relaxed • **Augment** App + relaxed + Nutritional Coaching (NC) Non-responders to App + stringent in Stage 1are randomized to either: • **Continue** App + stringent • **Augment** App + Stringent + NC Stage 2 responders **continue** original intervention Stage 2 non-responders who were assigned App + relaxed in Stage 1 are	Mobile application and coach uptake, retention rate at week 5, app engagement, and carbohydrate periodization behavior at week 5	Self-reported weight, goal, carbohydrate periodization self-efficacy, and belief about consequences	Impact of personality and need for autonomy on application usage, cost-effectiveness, feasibility

			randomized to either: • **Continue** App + relaxed • **Augment** App + relaxed + NC Stage 2 non-responders were who assigned App + stringent in Stage 1 are randomized to either: • **Continue** App + stringent • **Augment** App + stringent + NC			
Zhao SZ et al., 2022(71)	• PIM: Personalized instant messaging including real-time interactive conversation with smoking cessation conselors • RIM: Regular instant messaging with generic, fixed-schedule messages on smoking cessation	Non-responders were those still smoking at one month follow-up	Responders **continue** stage 1 intervention Non-responders to PIM were re-randomized to either: • **Switch** to OCI: Optional combined intervention, where participants can choose from a number of interventions or combinations thereof • **Continued** PIM Non-responders to RIM were re-randomized to either: • **Continue** RIM • **Switch** to PIM	Biochemically validated abstinence at 6 months after treatment initiation using exhaled carbon monoxide (<4 ppm) and salivary cotinine (<10 ng/ml)	Validated abstinence at 3 months (end of treatment), self-reported past 7 days abstinence, smoking reduction by at least 50% of baseline consumption, quit attempt (abstinence for ≥24 h), and smoking cessation services use, defined by any use of provided treatments (e.g. counselling, medication, acupuncture)	Patient experience, adherence
Zhou G et al., 2020(72)	• LLIN: Long-lasting insecticidal nets • PRO LLIN: Piperonyl butoxide-treated long-lasting insecticidal nets • LLIN + IRS: Long-lasting insecticidal nets combined with indoor residual spraying of Actellic 300CS	Responders are clusters with a statistically significant reduction in malaria incidence and greater than the pre-defined threshold value set by the Ministry of Health of Kenya Non-responders are clusters that do not meet the responder criteria	Those original randomized to LLIN **continue** LLIN in stage 2 PBO LLIN responders **continue** PBO LLIN in stage 2 Non-responders to PRO LLIN are re-randomized to either: • **Augment** PBO LLIN + larval source management (LSM) • **Switch** to enhanced method: an intervention determined adaptively based on stage 1 effectiveness analyses LLIN + IRS responders **continue** LLIN + IRS Non-responders to LLIN + IRS are re-randomized to either: • **Augment** to LLIN + IRS + LSM	Clinical malaria incidence rate	Malaria vector abundance and transmission intensity	Cost-effectiveness

			• **Augment** to PRO LLN + IRS			
Zullig LL et al., 2021(73)	• iGuide intervention (self-guided) • Control	Non-responders: PCP clinics with 90% or more of their participating patients do not meet the modified HEDIS quality metrics at the 6-month measurement Stage 1 non-responders are re-randomized	Those originally randomized to control **continue** control iGuide responders continue iGuide intervention in stage 2 Non-responders to stage 1 iGuide intervention are re-randomized to either: • **Continue** iGuide • **Step up** to iGuide 2 (tailored and targeted)	Health Effectiveness Data and Information Set (HEDIS), Proportion of Days Covered (PDC), Patient-centered Communication in Cancer (PCC-Ca-36)	Self-reports of medication adherence, cancer care-related financial toxicity, out-of-pocket expenses by category of spending, engagement, and care coordination	Cost, patient engagement, care coordination
Primary analysis papers						
Butzer JF et al., 2023(74)	• Bridge program (personalized approach) • Structured-exercise program (group-based)	All participants were re-randomized	All participants were re-randomized to either: • **Switch** to Relapse Prevention Group • **Switch** to no Relapse Prevention Group (control)	Time and intensity of postintervention physical activity and psychosocial assessments of depression, anxiety, self-efficacy, and function	Cardiovascular fitness measured with the Fatigue Index derived from the Wingate Anaerobic Test	NA
Czyz EK et al., 2021(75)	• Motivational Interviewing-Enhanced Safety Plan (MI-SP) Plus Text-based support (MI-SP + texts) • MI-SP Only	All participants were re-randomized	All participants were re-randomized to either: • First stage intervention **augmented** with booster calls • **Continue** first stage intervention (no booster calls)	NA	NA	Primary, secondary, and exploratory/tertiary outcomes were not distinguished. Mechanisms of change: safety plan use, coping, self-efficacy Distal: suicidal ideation and behavior
Fatori D et al., 2018(76)	• Fluoxetine (FLX) • Group cognitive-behavioral therapy (GCBT)	Non-responders are those with less than 50% reduction in baseline Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores	Non-responders were re-randomized to either: • **Switch** to the other first-stage treatment • **Augment** intial treatment with the other first-stage treatment Responders receive no further intervention	Severity of obsessive-compulsive symptoms (Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) at baseline, weeks 7, 14, 21, and 28.	NA	Safety/adverse events

Fortney JC et al., 2021(77)	• Telepsychiatry/Telepsycholoy-enhanced referral (TER): Telepsychiatrists assumed responsibility for treatment • Telepsychiatry Collaborative Care (TCC): Telepsychiatrists provided consultation to the primary care team	Non-responders: Patients assigned to TER with <= 2 telehealth encounters	Everyone randomized to TCC and TER responders received no further intervention TER non-responders were randomized to either: • **Continue** TER • **Switch** to Phone Enhanced Referral (PER): telephone outreach by pscyhologist aimed to increase patient engagement in treatment	Veterans RAND 12-item Health Survey Mental Component Summary (MCS) score	PTSD Checklist-5 (PCL-5) for PTSD, Hopkins Symptom Checklist (SCL-20) for depression, Altman Mania Rating Scale (AMRS) for mania, Internal State Scale (ISS) for mood state, General Anxiety Disorder-7 for general anxiety, Recovery Assessment Scale, and number of moderate and severe adverse effects from psychotropic medications	Accessibility, engagement, and adherence
Gao K et al., 2020(78)	• Lithium monotherapy (Li) • Divalproex monotherapy (Div)	Non-responders: Participants who continued to have clinically significant depression (CGI-S-BD depression score >=3 for 2 weeks at any time after the initial 2-week period)	Responders **continue** their first stage intervention Non-responders were randomized to: • **Continue** first stage therapy • Mood stabilizer (Li or Div) **augmented** with adjunctive quetiapine (QTP) • Mood stabilizer (Li or Div) **augmented** with adjunctive lamotrigine (LTG)	NA	NA	Primary and secondary outcome measures were not specified. The rates of early termination and time to termination after randomization were used to measure effectiveness of each intervention. Changes from baseline to the end of study in BISS and CGI-S-BD scores were used to measure the efficacy of each intervention.
Geng EH et al., 2023(79)	• Standard of Care (SOC) Oureach • Short Message Service (SMS) • Conditional Cash Transfers (CCT)	Responders did not have a retention lapse (missed a scheduled clinic visit by day 14 or more)	SOC responders **continue** SOC, while SOC non-responders are re-randomized to: • **Continue** SOC-Outreach • **Switch** to SMS+CCT • **Switch** to peer navigation Responders to SMS or CCT were re-randomized to either: • **Continue** with first-stage intervention • **Discontinue** first-stage intervention Non-responders to SMS or CCT were re-	Stage 1: retention in care without lapse (>= 14 days late for an appointment) for 1 year following initial randomization Stage 2a: Among those with a retention lapse, return to clinic by 1 year following randomization	Stage 1: Composite of viral suppression and retention at the end of year 2 Stage 2a (among those with a lapse by end of 1 year), Stage 2b (among those without a lapse by end of 1 year), full SMART: adjudicated viral suppression 2 years after enrollment	NA

			randomized to either: • **Switch** to SOC-Outreach • Initial intervention **augmented** with the other stage 1 intervention • **Switch** to Peer Navigation	Stage 2b: Among those with no lapse in year 1 wile in either the SMS or CCT group, retention in care without lapse for 1 year following randomization Comparision of the 15 adaptive strategies: proportion of time spent actively engaged in care (proportion of days during 2-year follow-up pateint was alive and had not been 14 days or more later for a scheduled appointment)		
Gonze BB et al., 2020(80)	• Pacer App only • App+tailored messages • Control group	To define responders and non-responders in this study, a linear regression was fitted for each participant with the relationship between weeks on the x-axis and the number of steps per day on the y-axis. Responders were with any positive slope at the end of the 12-week first stage of the intervention. Those with zero or negative slopes were considered as non-responders.	Responders **continue** their initial intervention Non-responders to either active treatment were randomized to **switch** to one of the following which was not the same as the assigned first stage intervention: • Pacer App only • App+tailored messages • App + tailored messages + gamification	NA	NA	Feasibility, participant perceptions
Gunlicks-Stoessel M et al., 2019(81)	• Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) assessed at 4 weeks (early): 12-session evidence-based psychotherapy aimed to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal	Non-responders: <20% reduction in Hamilton Rating Scale for Depression (HRSD) at week 4 or <40% reduction in HRSD score at week 8)	Responders **continue** IPT-A Non-responders are randomized to either: • **Step up** frequency of IPT-A • **Augmentation** of IPT-A with fluoxetine	Children's Global Assessment Scale-Revised (CDRS-R)	(Children's Global Assessment Scale) CGAS, (Social Adjustment Scale-Self Report) SAS-SR	Safety (Harm and suicide-related adverse events)

	interactions • Interpersonal Psychotherapy for Depressed Adolescents (IPT-A) assessed at 8 weeks (late)					
Igudesman D et al., 2023(82)	• Hypocaloric Low-carbohydrate diet • Hypocaloric Look AHEAD diet (moderate low-fat) • Mediterranean diet	Non-responders: <2% weight reduction (unless weight loss resulted in a body mass index <25 kg/m2), HbA1c increase ≥0.5% and self-reported increased or problematic hypoglycaemia and self-reported diet unacceptability	All non-responders were randomized to **switch** one of the alternative diets	Change in weight (kg), haemoglobin A1c (HbA1c) level, and percentage of time below range (%TBR; <70 mg/dl) as assessed by continuous glucose monitoring (CGM) at baseline and following each of three, 3-month, dietary periods	Change in percentage body fat as assessed by dual-energy X-ray absorptiometry (DXA), percentage of time in target glucose range (%TIR; 70-180 mg/dl) and %TBR (<54 mg/dl)	Percentage of time above range (%TAR; glucose levels 181-250 mg/dL and >250 mg/dL), coefficient of variation (CV) in glucose levels as measured by CGM
Karp JF et al., 2019(83)	• Cognitive Behavioral Therapy (CBT) • Physical Therapy (PT) • Enhanced Usual Care (EUC)	Non-responders: Lack of clinically significant response to the interventions defined as (1) much better or (2) very much better on the P-GIC	Everyone randomized to EUC and responders to CBT and PT receive no further intervention CBT and PT non-responders are re-randomized to either: • **Continue** stage 1 treatment • **Switch** to the other treatment	Patient-reported global impression of change (P-GIC)	Changes in depressive symptoms (PHQ-9), changes in anxiety symptoms (GAD-7), pain (numeric rating scale)	NA
Kruse GR et al., 2023(84)	• SMS with early assessment • SMS with late assessment	Non-responders: Not achieving 7 days abstinence from cigarettes	Responders receive no further intervention Non-responders were randomized to either: • SMS **augmented** with Nicotine replacement therapy (NRT) • SMS **augmented** with NRT + one session with behavioral coach	Self-reported 7 day point prevalent abstinence (PPA) at 12-weeks	Not explicitly labeled as secondary: 7-day PPA at 4- and 8-weeks, number of last 30 days with no smoking, use of cessation treatments, changes in cigarettes per day, motivation, confidence to quit, distress, biochemically verified abstinence	Feasibility, intervention fidelity, intervention engagement, treatment acceptability
Lambert SD et al., 2022(85)	• Website only • Website + coach	Non-responders: Stress score did not improve by at least 50% or who were not below the threshold DASS score of 16	Responders **continue** initial intervention Non-responders were re-randomized to either: • **Continue** initial intervention • **Switch** to Website + Motivational Interviewing (MI)	Stress and quality of life	Self-efficacy, patient illness appraisal, individual coping strategies, self-reported activity levels	Feasibility, acceptability, fidelity of the coaching intervention
McKay JR	Those not engaged at 2 weeks and those who	Week 2 Non-responders:	Those in the disengaged in weeks 3-8	Alcohol and drug use	NA	Attendance

et al., 2015(86)	are engaged at 2 weeks, but disengaged in weeks 3-8 are initially randomized to: • MI-OP: Motivational Interviewing – Intensive Outpatient Program, telephone calls that focused on engagement in IOP • MI-PC: Motivational Interviewing – Patient Choice, telephone calls giving participants the choice between continuing IOP or selecting one of three treatments (cognitive-behavioral therapy (CBT), telephone stepped care (TSC), or medication management (MM))	Failed to attend 2 or more IOP sessions in week 2 or failed to attend the second orientation and the first scheduled IOP session Week 3-8 Non-responders: Initially engaged but failed to attend any IOP sessions for two consecutive weeks Week 2 and week 8 Non-responders: Not engaged at week 2 and also failed to attend any IOP sessions in weeks 7 and 8	group are not re-randomized Responders in the not engaged at 2 weeks group received no further intervention Non-responders who disengaged at both weeks 2 and 8 were randomized to either: • **Continue** or **switch** to MI-PC • **Switch** to no further outreach	within each 30-day period of follow-up. For participants with alcohol dependence, the outcomes were dichotomous measures of any alcohol and any heavy alcohol use, and continuous measures of percent days alcohol and heavy alcohol use from the TLFB. Heavy alcohol use was defined as ≥ 5 drinks in a day for men, ≥ 4 drinks for women. For participants with cocaine dependence, the outcomes were a dichotomous measure of any cocaine use and percent days cocaine use from the TLFB, and cocaine urine toxicology		
Morgenstern J et al., 2021(87)	• MI: Motivational interviewing • BA Plus: An additional Brief Advice session	Responders were defined as reducing their drinking to the level of the NIAAA safe drinking guidelines, i.e. for men under the age of 65; <=14 standard drinks per week and <5 standard drink on one occasion; women and men over the age of 65 <= 7 standard drinks per week and <4 standard drinks on one occasion.	Responders receive no further intervention Non-responders to BA Plus were re-randomized to either: • **Switch** to two sessions of MI • **Switch** to five sessions of MI with four sessions of behavioral self-control therapy (BSCT) Non-responders to MI were randomized to either: • **Continue** MI for an additional session • **Switch** to four sessions of BSCT Responders did not receive further treatment	NA	NA	Primary, secondary, and exploratory/tertiary outcomes were not distinguished. Sum of standard drinks (SSD) and count of heavy drinking days (HDD) for the week prior to the affiliated assessment period (baseline, week 4, week 8, and week 13).

Morin CM et al., 2020(88)	• Behavioral Therapy (BT): sleep restriction and stimulus control procedures • Zolpidem: medication therapy	Responders: reduction of 8 points or more on the Insomnia Severity Index (ISI) compared with baseline	Responders receive no further intervention Non-responders to Zolpidem were re-randomized to either: • **Continue** with Zolpidem • **Switch** to Trazodone Non-responders to BT were randomized to either: • **Continue** with BT • **Switch** to Cognitive Therapy (CT)	Treatment response and remission rates, defined by the Insomnia Severity Index total score. Response was defined at each assessment as a reduction of 8 points or more on the ISI compared with baseline score. Remissions was defined at each assessment as an ISI score less than 8.	Secondary endpoints were derived from sleep diaries	NA
Naar-King S et al., 2016	• Home-based Motivational Interviewing and Skills (HB-MIS) • Office-based Motivational Interviewing and Skills (OB-MIS)	Non-responders: Weight loss of less than 3% Responders: Weight loss greater than or equal to 3%	Non-responders were randomized to either: • **Switch** to continued skills (CS) • **Switch** to contingency management (CM) Responders received Relapse Prevention (RP)	Percent overweight	Treatment engagement	NA
Patrick ME et al., 2021(89)	• Personalized Normative Feedback (PNF) + Self-monitoring (SM) prior to first semester (early group) • PNF + SM during first month of first semester (late group) • Assessment only (control)	Non-responders: Report of heavy drinking (two or more instances of binge drinking or one or more instance of high-intensity drinking)	Assessment only controls **continue** assessment only Responders in the early and late group **continue** SM Non-responders are re-randomized to either: • **Switch** to resource email • **Switch** to online health coach	Frequence of binge drinking	Alcohol-related consequences, health services utilization	NA
Pelham Jr WE et al., 2016(90)	• BehFirst: Low-intensity behavior modification • MedFirst: Low dose medication	Non-responder: child experienced continued impairment in the school and/or home setting	All responders continue initial intervention and reassess monthly; randomize if deteriorate Non-responders to BehFirst are randomized to either: • B-then-M: **Augment** with medication • B-then-B: **Step up** behavior modification Non-responders to MedFirst are randomized to either:	Classroom rule violations	Number of out-of-class disciplinary events, parent teacher ratings	Fidelity

			• M-then-B: **Augment** with behavior modification • M-then-M: **Step up** the medication dose			
Pistorello J et al., 2017(91)	• Collaborative Assessment and Management of Suicidality (CAMS): suicide-specific, collaborative approach to identify suicidal "drivers" that are treated over the course of care • Treatment-as-usual (TAU): customary treatment a study counselor would use in regular clinical practice	Responders: an Improvement score of ≤ 2 (much improved or very much improved) combined with a Severity score of ≤ 3 (Not at all suicidal, minimally suicidal, or mildly suicidal)	Responders proceed to monitoring, post and follow-up Non-responders were randomized to either: • **Continue** or **switch** to CAMS • **Switch** to comprehensive Dialectical Behavioral Therapy (DBT): individual and group sessions along with peer consultation meetings for therapists and as-needed phone/text coaching	Feasibility of the study in terms of participant recruitment (numbers and diversity) and clinician adherence to treatment, and the acceptability of the adaptive strategies in terms of clients' attendance, treatment dropout, and response to treatment and clients' and clinicians' satisfaction with treatment	NA	Stage 2 satisfaction and treatment response
Sauer-Zavala S et al., 2022(92)	• Standard condition (fixed standard order as described in the Unified Protocol manual) • Capitalization condition (strength-based sequencing) • Compensation condition (deficit-based sequencing)	All participants were randomized to the second stage which was solely based on session timing	All participants were re-randomized to **switch** to: • Brief treatment (6 sessions total) • Full treatment (12 sessions total)	• Primary outcomes were not distinguished	• Secondary outcomes were not distinguished	• Clinical severity rating (CSF), Overall anxiety severity and impairment scale (OASIS), Overall depression severity and impairment scale (ODSIS), feasibility, acceptability, satisfaction

Schlam TR et al., 2024(93)	All participants initially received a smoking cessation treatment. Participants that relapsed after the initial treatment were randomized to either: • Preparation Treatment (Active) • Recycling Treatment • Quitline referral (control)	Non-responders (relapse) to be eligible for the first randomization: smoking on seven consecutive days at any time up to 6 months after the initial quit attempt. Transition to the second randomization depended on participants' decision to attempt quitting again.	Controls do not receive further intervention Optional randomization for those initially randomized to Preparation or Recycling who also want to make another quit attempt. Participants received 8 weeks of nicotine patches plus mini-lozenges and were randomly assigned in a 2x2 factorial design to **switch** to: • Skill training (on/off) • Supportive counseling (on/off)	CO-confirmed 7-day point-prevalence abstinence 14 months post-phase 2 treatment initiation	Self-reported 7-day point-prevalence abstinence at week 26 post the phase 3 TQD	Abstinence at earlier time points, treatment re-engagement
Schmitz JM et al., 2024(94)	• Acceptance and Commitment Therapy (ACT) + Contingency Management (CM) • Drug counseling (DC) + CM	Responders: submit 6 consecutive cocaine-negative urine drug screens	Responders continue phase 1 intervention in phase 2 Non-responders to ACT are re-randomized to either • ACT + CM **augmented** with Modafinil (MOD) • ACT + CM **augmented** with placebo (PLA) Non-responders to DC + CM were randomized to either • DC + CM **augmented** with MOD • DC + CM **augmented** with PLA	Response rate defined as two weeks of consecutive abstinence by the end of Phase 1 and proportion of cocaine-negative UDS for phase 1 and 2	Reduction in cocaine use	Retention, adverse events, adherence
Schoenfelder EN et al., 2019(95)	• Maternal stimulant medication (MSM) • Behavioral parent training (BPT)	All families were re-randomized regardless of initial response	All families re-randomized to either: • **Continue** with first-stage intervention • **Augment** first-stage intervention with the other first-stage intervention	NA	NA	Feasibility, acceptability
Sherwood NE et al., 2022(96)	• State-of-the-art Behavioral Weight Loss Treatment (SBT) with early assessment: assessment at 3 weeks • SBT with late assessment: assessment at 7 weeks	Non-responders to Early TRA: lost less than 2.5% of their session 1 weight by Session 3 or 28 days following Session 1, which ever came first. Non-responders to Late TRA: lost less than 5.0% of	Responders **continued** with SBT Non-responders were randomized to either **switch** to: • Portion-controlled meals (PCM) • Acceptance-based Behavioral Treatment (ABT)	Body weight change from baseline at 6 months and 18 months	NA	Adherence, process/implementation, avoidance of treatment contamination, satisfaction and perceived helpfulness, safety/adverse events

		their session 1 weight by Session 7 or 63 days following Session 1, whichever came first.				
Sikorskii A et al., 2023(97)	• Symptom Management and Survivorship Handbook (SMSH) • SMSH combined with Telephone Interpersonal Counseling (TIP-C)	Non-responders to SMSM: Survivors who started at severe at baseline and ended at moderate or none/mild at week four, and survivors who started at moderate and ended at none/mild, were categorized as responders after four weeks of the SMSH.	Those in the TIP-C group did not receive additional intervention Responders to SMSH **continued** SMSH Non-responders to SMSH were re-randomized to either: • **Continue** SMSH alone • SMSH **augmented** with TIP-C	Depressive symptoms and a summary index of severity of other symptoms during weeks one to 13	Secondary outcomes were not distinguished	PROMIS short forms for physical function (4 items), anxiety (8 items)
Smith SN et al., 2022(98)	• Replicating Effective Programs (REP) • REP + Coaching	Non-responders: Any SP at a particular school not providing >=3 CBT components to >=10 students or SPs at a particular school reporting on average >2 barriers to CBT delivery or any SP at a particular school failed to complete the monitoring assessment	Responders continue phase 1 intervention in phase 2 Non-responders are re-randomized to either: • **Continue** phase 1 intervention • Phase 1 intervention **augmented** with facilitation All participants continue REP in phase 3	Total number of SP-reported CBT sessions delivered to students by SPs over the 18-month study period	Number of CBT sessions delivered by type of session: group vs. individual brief vs. individual full	Implementation
Somers TJ et al., 2023(99)	• Pain Coping Skills Training Full (PCST-Full): Five weekly 60-minute sessions • Pain Coping Skills Training Brief (PCST-Brief): One 60-minute session	Non-responders: <30% reduction or an increase in pain severity after first intervention	Responders to PCST-Full were re-randomized to either: • **Continue** PCST-Full (maintenance) • No further intervention Non-responders to PCST-Full were re-randomized to either: • **Step up** to PCST-Plus: two additional sessions • **Continue** PCST-Full (maintenance) Responders to PCST-Brief were randomized to either: • **Continue** PCST-Brief (maintenance) • No further intervention Non-responders to PCST-Brief were	Brief Pain Inventory – pain severity subscale (percent change in pain severity from Assessment 1 to Assessment 2)	NA	Adherence, skills practice

			randomized to either: • **Step up** to PCST-Full • **Continue** PCST-Brief (maintenance)			
Stanger C et al., 2020(100)	• STANDARD contingency management (CM) alone • STANDARD CM + working memory training (WMT)	Responders: Youth who were abstinent in Week 4 Non-responders: Youth who were not abstinent in Week 4	Responders **continued** their Phase 1 intervention Non-responders were randomized to either: • **Continue** standard CM • **Step up** to enhanced CM Assignment to WMT or no WMT was unchanged in stage 2	Primary outcomes were not distinguished	Secondary outcomes were not distinguished	Cannabis use and abstinence, working memory
Wyatt G et al., 2021(101)	• Reflexology • Meditative practices • Control (usual care)	Responders: had improvement in fatigue from moderate to mild or severe to moderate	Those receiving usual care **continued** usual care Responders to reflexology or meditative practices **continued** their initial treatment Non-responders to reflexology were re-randomized to either: • **Continue** reflexology • **Augment** reflexology with meditative practices Non-responders to meditative practices were re-randomized to either: • **Continue** meditative practices • **Augment** meditative practices with reflexology	Fatigue severity from the 9-item Brief Fatigue Inventory	Summed Symptom Severity Index (depression, anxiety, and the severity index of other symptoms)	Physical function and cancer and its treatment

Table 3. Summary of operational characteristics described

Characteristics	Protocol papers (n = 59) N (%)	Primary analysis papers (n = 29) N(%)
Sample size		
Was a sample size calculation reported?	55 (93.2%)	NA
If reported, did the sample size calculation account for multiple randomizations?	44 (74.6%)	NA
Blinding/masking		
Was blinding or lack of blinding described?	38 (64.4%)	20 (69.0%)
Randomization		
Reported 1st stage allocation ratio	33 (55.9%)	15 (51.7%)
Reported 2nd stage and/or tertiary stage allocation ratio	31 (52.5%)	11 (37.9%)
Any stratification used?	27 (45.8%)	9 (31.0%)
Any minimization used?	2 (3.4%)	3 (10.3%)
Any blocking used?	33 (55.9%)	6 (20.7%)
No details reported	7 (11.9%)	7 (24.1%)

Table 4. Summary of embedded and deeply tailored regimes in primary analysis papers

Characteristic	**Number of primary analysis papers (%)**
Analyzed embedded regimes	14 (48.3%)
Statistical methods for embedded regimes • Weighting and replication • G-computation • Marginal, weighted least squares • Longitudinal TMLE • GEE-based methods • Cubic polynomial modeling	 9 (31.0%) 1 (3.4%) 1 (3.4%) 1 (3.4%) 1 (3.4%) 1 (3.4%)
Analyzed deeply tailored regimes	0 (0.0%)

Figure 1. Generic SMART schematic



Caption: In this example of a particular SMART design, a trial participant may initially be randomized to one of two treatments, A or B. After 3 months, they are assessed for response to the initial treatment. If they have a positive treatment response, they will be assigned to remain on their initial treatment. Otherwise, they are re-randomized to either switch treatment or receive an augmented version of their initially assigned treatment.

Figure 2. PRISMA flow diagram



Old PRISMA:


5509 studies imported into Covidence for screening
2 duplicates identified manually
21 duplicates identified by Covidence
5509 studies imported into Covidence for title and abstract screening
4657 studies excluded during title and abstract screening
829 full-text studies assessed for eligibility
532 studies excluded during full-text screening
• 472 Did not refer to design as a SMART
• 56 Reviews, commentaries, editorials, letters, dissertations/theses
• Interventions not randomized
• Article not in English
297 studies assessed for inclusion in full-text extraction
209 excluded during assessment for inclusion in full-text extraction
• 132 websites or registry entries
• 54 secondary analysis papers
• 13 protocol corresponding to a primary analysis paper
• 6 Reviews, commentaries, editorials, letters, dissertations/theses
• 2 Methodological paper
• 1 preprint
• 1 Not human health
88 studies assessed for inclusion in full-text extraction
• 59 protocol papers
• 29 primary analysis papers

References

1. Kosorok MR, Moodie EEM. Adaptive Treatment Strategies in Practice: Planning Trials and Analyzing Data for Personalized Medicine. SIAM; 2015. 364 p.

2. Murphy SA, Bingham D. Screening experiments for developing dynamic treatment regimes. J Am Stat Assoc. 2009 Mar 1;104(485):391–408.

3. Kidwell KM, Almirall D. Sequential, multiple assignment, randomized trial designs. JAMA. 2023 Jan 24;329(4):336–7.

4. Chakraborty B, Moodie EEM. Statistical Methods for Dynamic Treatment Regimes. Springer New York; 2013. 16 p.

5. Tsiatis AA, Davidian M, Holloway ST, Laber EB. Dynamic treatment regimes: Statistical methods for precision medicine. Chapman and Hall/CRC; 2019.

6. Lorenzoni G, Petracci E, Scarpi E, Baldi I, Gregori D, Nanni O. Use of Sequential Multiple Assignment Randomized Trials (SMARTs) in oncology: systematic review of published studies. Br J Cancer. 2023 Mar;128(7):1177–88.

7. Bigirumurame T, Uwimpuhwe G, Wason J. Sequential multiple assignment randomized trial studies should report all key components: a systematic review. J Clin Epidemiol. 2022 Feb 1;142:152–60.

8. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for Scoping Reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018 Oct 2;169(7):467–73.

9. Freeman NLB, Rowland BT, Jones EP, Bryant A, Cleven A, Zhou C, et al. Reporting characteristics of sequential multiple assignment randomized trials (SMARTs) for human health: a scoping review of studies between 2009-2023 [Internet]. 2023 Sep. Available from: https://doi.org/10.17605/OSF.IO/J25AF

10. Bhatti MM, Kiran T, Ahmad B, Waqas A, Husain N. Methodological Characteristics of Sequential Multiple Random Assignment Trials Evaluating Psychosocial Interventions for Common Mental Disorders: A Systematic Review [Internet]. PROSPERO; 2024. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023432833

11. Kim B, Song Y. Systematic review and meta-analysis of smart design research for humans [Internet]. PROSPERO; 2024. Available from: https://www.crd.york.ac.uk/PROSPERO/view/CRD42021256306

12. Hopewell S, Chan A-W, Collins GS, Hróbjartsson A, Moher D, Schulz KF, et al. CONSORT 2025 statement: Updated guideline for reporting randomized trials: Updated guideline for

reporting randomized trials. JAMA [Internet]. American Medical Association (AMA); 2025 Apr 14 [cited 2025 Apr 27]; Available from: http://dx.doi.org/10.1001/jama.2025.4347

13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021 Jun;134:178–89.

14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies: Guidelines for reporting observational studies. Epidemiology. 2007 Nov;18(6):800–4.

15. Abuogi LL, Kulzer JL, Akama E, Odeny TA, Eshun-Wilson I, Petersen M, et al. Adapt for Adolescents: Protocol for a sequential multiple assignment randomized trial to improve retention and viral suppression among adolescents and young adults living with HIV in Kenya. Contemp Clin Trials. 2023;127:107123.

16. Arean P, Hull D, Pullmann MD, Heagerty PJ. Protocol for a sequential, multiple assignment, randomised trial to test the effectiveness of message-based psychotherapy for depression compared with telepsychotherapy. BMJ Open. 2021;11(11):e046958.

17. August GJ, Piehler TF, Bloomquist ML. Being “SMART” About Adolescent Conduct Problems Prevention: Executing a SMART Pilot Study in a Juvenile Diversion Agency. J Clin Child Adolesc Psychol. 2016;45(4):495–509.

18. Auyeung SF, Long Q, Royster EB, Murthy S, McNutt MD, Lawson D, et al. Sequential multiple-assignment randomized trial design of neurobehavioral treatment for patients with metastatic malignant melanoma undergoing high-dose interferon-alpha therapy. Clin Trials. 2009;6(5):480–90.

19. Bahraini NH, Matarazzo BB, Barry CN, Post EP, Forster JE, Dollar KM, et al. Protocol: examining the effectiveness of an adaptive implementation intervention to improve uptake of the VA suicide risk identification strategy: a sequential multiple assignment randomized trial. Implement Sci. 2020;15(1):58.

20. Belzer ME, MacDonell KK, Ghosh S, Naar S, McAvoy-Banerjea J, Gurung S, et al. Adaptive Antiretroviral Therapy Adherence Interventions for Youth Living With HIV Through Text Message and Cell Phone Support With and Without Incentives: Protocol for a Sequential Multiple Assignment Randomized Trial (SMART). JMIR Res Protoc. 2018;7(12):e11183.

21. Berget C, Driscoll KA, Lagges A, Lange S, DiMeglio LA, Hannon TS, et al. Optimizing the use of continuous glucose monitoring in young children with type 1 diabetes with an adaptive study design and multiple randomizations. Contemp Clin Trials. 2019;82:60–5.

22. Buchholz SW, Wilbur J, Halloway S, Schoeny M, Johnson T, Vispute S, et al. Study protocol for a sequential multiple assignment randomized trial (SMART) to improve physical activity in employed women. Contemp Clin Trials. 2020;89:105921.

23. Carr E, Whiston A, O'Reilly S, O. Donoghue M, Cardy N, Carter D, et al. Sequential multiple assignment randomised trial to develop an adaptive mobile health intervention to increase physical activity in people poststroke in the community setting in Ireland: TAPAS trial protocol. BMJ Open. 2024;14(1):e072811.

24. Comins CA, Schwartz SR, Phetlhu DR, Guddera V, Young K, Farley JE, et al. Siyaphambili protocol: An evaluation of randomized, nurse-led adaptive HIV treatment interventions for cisgender female sex workers living with HIV in Durban, South Africa. Res Nurs Health. 2019;42(2):107–18.

25. Davis-Ewart L, Grov C, Verhagen R, Manuel J, Viamonte M, Dilworth S, et al. Motivational Enhancement Interventions to Increase Pre-Exposure Prophylaxis Use in Sexual Minority Men Who Use Stimulants: Protocol for a Pilot Sequential Multiple Assignment Randomized Trial. JMIR Res Protoc. 2023;12:e48459.

26. Doorenbos AZ, Schlaeger JM, deMartelly VA, Burke LA, Boyd AD, Knisely MR, et al. Hybrid effectiveness-implementation trial of guided relaxation and acupuncture for chronic sickle cell disease pain (GRACE): A protocol. Contemp Clin Trials Commun. 2023;32:101076.

27. Drake CL, Kalmbach DA, Cheng P, Ahmedani BK, Peterson EL, Joseph CLM, et al. Sleep to Reduce Incident Depression Effectively (STRIDE): study protocol for a randomized controlled trial comparing stepped-care cognitive-behavioral therapy for insomnia versus sleep education control to prevent major depression. Trials. 2022;23(1):967.

28. Edelman EJ, Dziura J, Deng Y, Bold KW, Murphy SM, Porter E, et al. A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study. Contemp Clin Trials. 2021;110:106379.

29. Eldridge-Smith ED, Manber R, Tsai S, Kushida C, Simmons B, Johnson R, et al. Stepped care management of insomnia co-occurring with sleep apnea: the AIR study protocol. Trials. 2022;23(1):806.

30. Fernandez ME, Schlechter CR, Del Fiol G, Gibson B, Kawamoto K, Siaperas T, et al. QuitSMART Utah: an implementation study protocol for a cluster-randomized, multi-level Sequential Multiple Assignment Randomized Trial to increase Reach and Impact of tobacco cessation treatment in Community Health Centers. Implement Sci. 2020;15(1):9.

31. Flynn D, Eaton LH, Langford DJ, Ieronimakis N, McQuinn H, Burney RO, et al. A SMART design to determine the optimal treatment of chronic pain among military personnel. Contemp Clin Trials. 2018;73:68–74.

32. Fox CK, Vock DM, Sherwood NE, Gross AC, Ryder JR, Bensignor MO, et al. SMART use of medications for the treatment of adolescent severe obesity: A sequential multiple assignment randomized trial protocol. Contemp Clin Trials. 2024;138:107444.

33. Fritz JM, Rhon DI, Teyhen DS, Kean J, Vanneman ME, Garland EL, et al. A Sequential Multiple-Assignment Randomized Trial (SMART) for Stepped Care Management of Low Back Pain in the Military Health System: A Trial Protocol. Pain Medicine. 2020;21(Suppl 2):S73-s82.

34. Fu SS, Rothman AJ, Vock DM, Lindgren B, Almirall D, Begnaud A, et al. Program for lung cancer screening and tobacco cessation: Study protocol of a sequential, multiple assignment, randomized trial. Contemp Clin Trials. 2017;60:86–95.

35. Germeroth LJ, Benno MT, Kolko Conlon RP, Emery RL, Cheng Y, Grace J, et al. Trial design and methodology for a non-restricted sequential multiple assignment randomized trial to evaluate combinations of perinatal interventions to optimize women's health. Contemp Clin Trials. 2019;79:111–21.

36. Hassett AL, Williams DA, Harris RE, Harte SE, Kaplan CM, Schrepf A, et al. An Interventional Response Phenotyping Study in Chronic Low Back Pain: Protocol for a Mechanistic Randomized Controlled Trial. Pain Medicine. 2023;24(Suppl 1):S126-s138.

37. Hibbard JC, Friedstat JS, Thomas SM, Edkins RE, Hultman CS, Kosorok MR. LIBERTI: A SMART study in plastic surgery. Clin Trials. 2018;15(3):286–93.

38. Inwani I, Chhun N, Agot K, Cleland CM, Buttolph J, Thirumurthy H, et al. High-Yield HIV Testing, Facilitated Linkage to Care, and Prevention for Female Youth in Kenya (GIRLS Study): Implementation Science Protocol for a Priority Population. JMIR Res Protoc. 2017;6(12):e179.

39. Jain S, He F, Brown K, Burns JC, Tremoulet AH. Multisystem Inflammatory Syndrome therapies in children (MISTIC): A randomized trial. Contemp Clin Trials Commun. 2023;32:101060.

40. Johnson JE, Wiltsey-Stirman S, Sikorskii A, Miller T, King A, Blume JL, et al. Protocol for the ROSE sustainment (ROSES) study, a sequential multiple assignment randomized trial to determine the minimum necessary intervention to maintain a postpartum depression prevention program in prenatal clinics serving low-income women. Implement Sci. 2018;13(1):115.

41. Kilbourne AM, Almirall D, Eisenberg D, Waxmonsky J, Goodrich DE, Fortney JC, et al. Protocol: Adaptive Implementation of Effective Programs Trial (ADEPT): cluster randomized SMART trial comparing a standard versus enhanced implementation strategy to improve outcomes of a mood disorders program. Implement Sci. 2014;9:132.

42. Kopelowicz A, Nandy K, Ruiz ME, Polzin R, Kurator K, Wali S. Improving Self-management of Type 2 Diabetes in Latinx Patients: Protocol for a Sequential Multiple Assignment Randomized Trial Involving Community Health Workers, Registered Nurses, and Family Members. JMIR Res Protoc. 2023;12:e44793.

43. Kor PPK, Chou KL, Zarit SH, Gallagher D, Galante J, Wong SYS, et al. Sequential multiple assignment randomised controlled trial protocol for developing an adaptive intervention to improve depressive symptoms among family caregivers of people with dementia. BMJ Open. 2023;13(9):e072410.

44. Levy R, Mathai M, Chatterjee P, Ongeri L, Njuguna S, Onyango D, et al. Implementation research for public sector mental health care scale-up (SMART-DAPPER): a sequential multiple, assignment randomized trial (SMART) of non-specialist-delivered psychotherapy and/or medication for major depressive disorder and posttraumatic stress disorder (DAPPER) integrated with outpatient care clinics at a county hospital in Kenya. BMC Psychiatry. 2019;19(1):424.

45. Li X, Guo X, Fan X, Feng T, Wang C, Yao Z, et al. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design. Schizophr Res. 2021;230:87–94.

46. Lion KC, Zhou C, Fishman P, Senturia K, Cole A, Sherr K, et al. A sequential, multiple assignment randomized trial comparing web-based education to mobile video interpreter access for improving provider interpreter use in primary care clinics: the mVOCAL hybrid type 3 study protocol. Implement Sci. 2023;18(1):8.

47. Liu H, Chen G, Li J, Hao C, Zhang B, Bai Y, et al. Sequential multiple assignment randomised trial of a brief contact intervention for suicide risk management among discharged psychiatric patients: an implementation study protocol. BMJ Open. 2021;11(11):e054131.

48. Markland AD, Vaughan CP, Goldstein KM, Hastings SN, Kelly U, Beasley TM, et al. Optimizing remote access to urinary incontinence treatments for women veterans (PRACTICAL): Study protocol for a pragmatic clinical trial comparing two virtual care options. Contemp Clin Trials. 2023;133:107328.

49. Micheletti RG, Pagnoux C, Tamura RN, Grayson PC, McAlear CA, Borchin R, et al. Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. Trials. 2020;21(1):362.

50. Nelson B, Amminger GP, Yuen HP, Wallis N, J. Kerr M, Dixon L, et al. Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients. Early Interv Psychiatry. 2018;12(3):292–306.

51. O'Keefe VM, Haroz EE, Goklish N, Ivanich J, Cwik MF, Barlow A. Employing a sequential multiple assignment randomized trial (SMART) to evaluate the impact of brief risk and

protective factor prevention interventions for American Indian Youth Suicide. BMC Public Health. 2019;19(1):1675.

52. Osilla KC, Gore KL, Pedersen ER, Hummer JF, DeYoreo M, Manuel JK, et al. Study protocol for a sequential multiple assignment randomized trial to reduce risky drinking among service members and their partners. Contemp Clin Trials. 2023;133:107324.

53. Peter SC, Murphy JG, Witkiewitz K, Hand SB, Thomas F, Johnson KC, et al. Use of a sequential multiple assignment randomized trial to test contingency management and an integrated behavioral economic and mindfulness intervention for buprenorphine-naloxone medication adherence for opioid use disorder. Trials. 2023;24(1):237.

54. Peterson BS, West AE, Weisz JR, Mack WJ, Kipke MD, Findling RL, et al. A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders. BMC Psychiatry. 2021;21(1):323.

55. Pfammatter AF, Nahum-Shani I, DeZelar M, Scanlan L, McFadden HG, Siddique J, et al. SMART: Study protocol for a sequential multiple assignment randomized controlled trial to optimize weight loss management. Contemp Clin Trials. 2019;82:36–45.

56. Quanbeck A, Almirall D, Jacobson N, Brown RT, Landeck JK, Madden L, et al. The Balanced Opioid Initiative: protocol for a clustered, sequential, multiple-assignment randomized trial to construct an adaptive implementation strategy to improve guideline-concordant opioid prescribing in primary care. Implement Sci. 2020;15(1):26.

57. Rabin BA, Cain KL, Watson P Jr, Oswald W, Laurent LC, Meadows AR, et al. Scaling and sustaining COVID-19 vaccination through meaningful community engagement and care coordination for underserved communities: hybrid type 3 effectiveness-implementation sequential multiple assignment randomized trial. Implement Sci. 2023;18(1):28.

58. Sabri B, Glass N, Murray S, Perrin N, Case JR, Campbell JC. A technology-based intervention to improve safety, mental health and empowerment outcomes for immigrant women with intimate partner violence experiences: it's weWomen plus sequential multiple assignment randomized trial (SMART) protocol. BMC Public Health. 2021;21(1):1956.

59. Schlechter CR, Del Fiol G, Jones DR, Orleans B, Gibson B, Nahum-Shani I, et al. Increasing the reach of evidence-based interventions for weight management and diabetes prevention among Medicaid patients: study protocol for a pilot Sequential Multiple Assignment Randomised Trial. BMJ Open. 2023;13(11):e075157.

60. Skolasky RL, Wegener ST, Aaron RV, Ephraim P, Brennan G, Greene T, et al. The OPTIMIZE study: protocol of a pragmatic sequential multiple assessment randomized trial of nonpharmacologic treatment for chronic, nonspecific low back pain. BMC Musculoskelet Disord. 2020;21(1):293.

61. Smith SK, Somers TJ, Kuhn E, Laber E, Sung AD, Syrjala KL, et al. A SMART approach to optimizing delivery of an mHealth intervention among cancer survivors with posttraumatic stress symptoms. Contemp Clin Trials. 2021;110:106569.

62. Sripada RK, Smith K, Walters HM, Ganoczy D, Kim HM, Grau PP, et al. Testing adaptive interventions to improve PTSD treatment outcomes in Federally Qualified Health Centers: Protocol for a randomized clinical trial. Contemp Clin Trials. 2023;129:107182.

63. Tamura K, Vijayakumar NP, Troendle JF, Curlin K, Neally SJ, Mitchell VM, et al. Multilevel mobile health approach to improve cardiovascular health in resource-limited communities with Step It Up: a randomised controlled trial protocol targeting physical activity. BMJ Open. 2020;10(12):e040702.

64. van Heerden A, Szpiro A, Ntinga X, Celum C, van Rooyen H, Essack Z, et al. A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa: the SMART ART study. Trials. 2023;24(1):32.

65. Velloza J, Poovan N, Ndlovu N, Khoza N, Morton JF, Omony J, et al. Adaptive HIV pre-exposure prophylaxis adherence interventions for young South African women: Study protocol for a sequential multiple assignment randomized trial. PLoS One. 2022;17(4):e0266665.

66. Walton MA, Carter PM, Seewald L, Ngo Q, Battisti KA, Pearson C, et al. Adaptive interventions for alcohol misuse and violent behaviors among adolescents and emerging adults in the emergency department: A sequential multiple assignment randomized controlled trial protocol. Contemp Clin Trials. 2023;130:107218.

67. Wan Y, Cai Y, Liao S, Zhao Q, Wang Y, Song X, et al. Smartphone-based versus traditional face-to-face collaborative care for community-dwelling older adults living with dementia in China: protocol for an implementation science-based sequential multiple assignment randomised trial. BMJ Open. 2023;13(7):e067406.

68. Wilroy J, Kim Y, Lai B, Young HJ, Giannone J, Powell D, et al. Increasing Physical Activity in Persons With Spinal Cord Injury With an eHealth-Based Adaptive Exercise Intervention: Protocol for a Sequential Multiple Assignment Randomized Trial. JMIR Res Protoc. 2023;12:e47665.

69. Windsor L, Benoit E, M. Pinto R, Sarol J. Optimization of a new adaptive intervention using the SMART Design to increase COVID-19 testing among people at high risk in an urban community. Trials. 2022;23(1):310.

70. Yan X, Dunne DM, Impey SG, Cunniffe B, Lefevre CE, Mazorra R, et al. A pilot sequential multiple assignment randomized trial (SMART) protocol for developing an adaptive coaching intervention around a mobile application for athletes to improve carbohydrate periodization behavior. Contemp Clin Trials Commun. 2022;26:100899.

71. Zhao SZ, Weng X, Luk TT, Wu Y, Cheung DYT, Li WHC, et al. Adaptive interventions to optimise the mobile phone-based smoking cessation support: study protocol for a sequential, multiple assignment, randomised trial (SMART). Trials. 2022;23(1):681.

72. Zhou G, Lee MC, Atieli HE, Githure JI, Githeko AK, Kazura JW, et al. Adaptive interventions for optimizing malaria control: an implementation study protocol for a block-cluster randomized, sequential multiple assignment trial. Trials. 2020;21(1):665.

73. Zullig LL, Shahsahebi M, Neely B, Hyslop T, Avecilla RAV, Griffin BM, et al. Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial. BMC Fam Pract. 2021;22(1):234.

74. Butzer JF, Kozlowski AJ, Hern R, Gooch C. Randomized Trial of Two Exercise Programs to Increase Physical Activity and Health-Related Quality of Life for Persons With Spinal Cord Injury. Top Spinal Cord Inj Rehabil. 2023;29(4):51–60.

75. Czyz EK, King CA, Prouty D, Micol VJ, Walton M, Nahum-Shani I. Adaptive intervention for prevention of adolescent suicidal behavior after hospitalization: a pilot sequential multiple assignment randomized trial. J Child Psychol Psychiatry. 2021;62(8):1019–31.

76. Fatori D, de Bragança Pereira CA, Asbahr FR, Requena G, Alvarenga PG, de Mathis MA, et al. Adaptive treatment strategies for children and adolescents with Obsessive-Compulsive Disorder: A sequential multiple assignment randomized trial. J Anxiety Disord. 2018;58:42–50.

77. Fortney JC, Bauer AM, Cerimele JM, Pyne JM, Pfeiffer P, Heagerty PJ, et al. Comparison of Teleintegrated Care and Telereferral Care for Treating Complex Psychiatric Disorders in Primary Care: A Pragmatic Randomized Comparative Effectiveness Trial. JAMA Psychiatry. 2021;78(11):1189–99.

78. Gao K, Arnold JG, Prihoda TJ, Quinones M, Singh V, Schinagle M, et al. Sequential Multiple Assignment Randomized Treatment (SMART) for Bipolar Disorder at Any Phase of Illness and at least Mild Symptom Severity. Psychopharmacol Bull. 2020;50(2):8–25.

79. Geng EH, Odeny TA, Montoya LM, Iguna S, Kulzer JL, Adhiambo HF, et al. Adaptive Strategies for Retention in Care among Persons Living with HIV. NEJM Evid [Internet]. 2023;2(4). Available from: http://dx.doi.org/10.1056/evidoa2200076

80. Gonze BB, Padovani RDC, Simoes MDS, Lauria V, Proença NL, Sperandio EF, et al. Use of a Smartphone App to Increase Physical Activity Levels in Insufficiently Active Adults: Feasibility Sequential Multiple Assignment Randomized Trial (SMART). JMIR Res Protoc. 2020;9(10):e14322.

81. Gunlicks-Stoessel M, Mufson L, Bernstein G, Westervelt A, Reigstad K, Klimes-Dougan B, et al. Critical Decision Points for Augmenting Interpersonal Psychotherapy for Depressed

Adolescents: A Pilot Sequential Multiple Assignment Randomized Trial. J Am Acad Child Adolesc Psychiatry. 2019;58(1):80–91.

82. Igudesman D, Crandell J, Corbin KD, Zaharieva DP, Addala A, Thomas JM, et al. Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results. Diabetes, Obesity & Metabolism. 2023;25(3):688–99.

83. Karp JF, Zhang J, Wahed AS, Anderson S, Dew MA, Fitzgerald GK, et al. Improving Patient Reported Outcomes and Preventing Depression and Anxiety in Older Adults With Knee Osteoarthritis: Results of a Sequenced Multiple Assignment Randomized Trial (SMART) Study. Am J Geriatr Psychiatry. 2019;27(10):1035–45.

84. Kruse GR, Joyce A, Yu L, Park ER, Neil J, Chang Y, et al. A pilot adaptive trial of text messages, mailed nicotine replacement therapy, and telephone coaching among primary care patients who smoke. J Subst Use Addict Treat. 2023;145:208930.

85. Lambert SD, Grover S, Laizner AM, McCusker J, Belzile E, Moodie EEM, et al. Adaptive web-based stress management programs among adults with a cardiovascular disease: A pilot Sequential Multiple Assignment Randomized Trial (SMART). Patient Educ Couns. 2022;105(6):1587–97.

86. McKay JR, Drapkin ML, Van Horn DH, Lynch KG, Oslin DW, DePhilippis D, et al. Effect of patient choice in an adaptive sequential randomization trial of treatment for alcohol and cocaine dependence. J Consult Clin Psychol. 2015;83(6):1021–32.

87. Morgenstern J, Kuerbis A, Shao S, Padovano HT, Levak S, Vadhan NP, et al. An efficacy trial of adaptive interventions for alcohol use disorder. J Subst Abuse Treat. 2021;123:108264.

88. Morin CM, Edinger JD, Beaulieu-Bonneau S, Ivers H, Krystal AD, Guay B, et al. Effectiveness of Sequential Psychological and Medication Therapies for Insomnia Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(11):1107–15.

89. Patrick ME, Lyden GR, Morrell N, Mehus CJ, Gunlicks-Stoessel M, Lee CM, et al. Main outcomes of M-bridge: A sequential multiple assignment randomized trial (SMART) for developing an adaptive preventive intervention for college drinking. J Consult Clin Psychol. 2021;89(7):601–14.

90. Pelham WE Jr, Fabiano GA, Waxmonsky JG, Greiner AR, Gnagy EM, Pelham WE 3rd, et al. Treatment Sequencing for Childhood ADHD: A Multiple-Randomization Study of Adaptive Medication and Behavioral Interventions. J Clin Child Adolesc Psychol. 2016;45(4):396–415.

91. Pistorello J, Jobes DA, Compton SN, Locey NS, Walloch JC, Gallop R, et al. Developing Adaptive Treatment Strategies to Address Suicidal Risk in College Students: A Pilot Sequential, Multiple Assignment, Randomized Trial (SMART). Arch Suicide Res. 2017;22(4):644–64.

92. Sauer-Zavala S, Southward MW, Stumpp NE, Semcho SA, Hood CO, Garlock A, et al. A SMART approach to personalized care: preliminary data on how to select and sequence skills in transdiagnostic CBT. Cogn Behav Ther. 2022;51(6):435–55.

93. Schlam TR, Baker TB, Piper ME, Cook JW, Smith SS, Zwaga D, et al. What to do after smoking relapse? A sequential multiple assignment randomized trial of chronic care smoking treatments. Addiction [Internet]. 2024; Available from: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.16428?download=true

94. Schmitz JM, Stotts AL, Vujanovic AA, Yoon JH, Webber HE, Lane SD, et al. Contingency management plus acceptance and commitment therapy for initial cocaine abstinence: Results of a sequential multiple assignment randomized trial (SMART). Drug Alcohol Depend. 2024;256:111078.

95. Schoenfelder EN, Chronis-Tuscano A, Strickland J, Almirall D, Stein MA. Piloting a Sequential, Multiple Assignment, Randomized Trial for Mothers with Attention-Deficit/Hyperactivity Disorder and Their At-Risk Young Children. J Child Adolesc Psychopharmacol. 2019;29(4):256–67.

96. Sherwood NE, Crain AL, Seburg EM, Butryn ML, Forman EM, Crane MM, et al. BestFIT Sequential Multiple Assignment Randomized Trial Results: A SMART Approach to Developing Individualized Weight Loss Treatment Sequences. Ann Behav Med. 2022;56(3):291–304.

97. Sikorskii A, Badger T, Segrin C, Crane TE, Chalasani P, Arslan W, et al. A Sequential Multiple Assignment Randomized Trial of Symptom Management After Chemotherapy. J Pain Symptom Manage. 2023;65(6):541-552.e2.

98. Smith SN, Almirall D, Choi SY, Koschmann E, Rusch A, Bilek E, et al. Primary aim results of a clustered SMART for developing a school-level, adaptive implementation strategy to support CBT delivery at high schools in Michigan. Implement Sci. 2022;17(1):42.

99. Somers TJ, Winger JG, Fisher HM, Hyland KA, Davidian M, Laber EB, et al. Behavioral cancer pain intervention dosing: results of a Sequential Multiple Assignment Randomized Trial. Pain. 2023;164(9):1935–41.

100. Stanger C, Scherer EA, Vo HT, Babbin SF, Knapp AA, McKay JR, et al. Working memory training and high magnitude incentives for youth cannabis use: A SMART pilot trial. Psychol Addict Behav. 2020;34(1):31–9.

101. Wyatt G, Lehto R, Guha-Niyogi P, Brewer S, Victorson D, Pace T, et al. Reflexology and meditative practices for symptom management among people with cancer: Results from a sequential multiple assignment randomized trial. Res Nurs Health. 2021;44(5):796–810.